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ABSTRACT 
Gangliosides are glycosphingolipids (GSLs) containing sialic acids that 
play numerous roles in neuronal maturation, apoptotic signaling, 
angiogenesis, and cell surface receptor activity.  The GM1 and GM2 
gangliosidoses are a series of autosomal recessive lysosomal storage 
disorders (LSDs) characterized by an inability to degrade these lipid 
molecules.  GM1 gangliosidosis is caused by a mutation in the 
lysosomal hydrolase β-galactosidase, resulting in neuronal storage of 
ganglioside GM1 and asialo GA1.  Tay-Sachs (TS) and Sandhoff 
Disease (SD) are GM2 gangliosidoses caused by mutations in either 
the α or β subunits, respectively, of the heterodimeric protein β-
hexosaminidase A, resulting in the storage of ganglioside GM2 and 
asialo GA2. The accumulation of excess ganglioside in the central 
nervous system leads to abnormal intracellular vacuoles, neuronal 
loss, demyelination, ataxia, dementia, and premature death.  In my 
studies, I have shown that accumulation of GM1 ganglioside may not 
coincide with secondary storage of cholesterol, by providing evidence 
that cholesterol-binding fluorescent molecule filipin reacted to GM1 
ganglioside in the absence of cholesterol.  In an effort to combat the 
early-onset gangliosidoses, I have explored the effects of combining 
Neural Stem Cells (NSCs) with Substrate Reduction Therapy (SRT) in 
juvenile Sandhoff mice.  The analysis showed that SRT was more 
effective than NSCs in reducing stored GM2 and GA2 in young mice, 
and no synergy was observed.  In adult GM1 gangliosidosis, Tay-
Sachs, and Sandhoff mice, Adeno-Associated Viral (AAV) vector gene 
therapy was used to restore therapeutic levels of wild-type enzyme to 
the CNS.  AAV therapy corrected ganglioside storage and ameliorated 
myelin-associated lipid loss in all tissues assayed, increasing motor 
performance and life in effected animals.  Lastly, AAV therapy was also 
successful in a feline model of Sandhoff disease.  These results in 
juvenile and adult model systems point the way towards multiple 
effective clinical therapies in the near future. 
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CHAPTER ONE 
 
INTRODUCTION 
Ganglioside Structure and Function 
Gangliosides are glycosphingolipids (GSLs) found primarily in 
plasma membranes of the grey matter in the central nervous system 
(Wiegandt 1967, Yu et al. 2011).  The basic GSL structure consists of 
sphingosine, an amide-linked saturated or monounsaturated fatty acid, 
and an O-linked oligosaccharide (Nelson, Cox & Lehninger 2005).  
GSLs are metabolized from ceramide (O-linked to a hydrogen atom) 
and structurally similar to sphingomyelin (O-linked to phosphocholine).  
The oligosaccharide chains generally consist of one to four molecules 
of glucose, galactose, N-acetylglucosamine, and N-
acetylgalactosamine.  The hydrophobic ceramide moiety is anchored to 
the lipid bilayer, while the hydrophilic sugars are exposed to the 
extracellular space (Maccioni, Giraudo & Daniotti 2002) (Figure 1).  
Gangliosides are differentiated from neutral glycosphingolipids 
by the presence of one or more sialic acids, either N-acetylneuraminic 
acid (NeuAc, or NANA) or N-glycoylneuraminic acid (NeuGC, or NGNA), 
which confer a negative charge at neutral pH (Nelson, Cox & Lehninger 
2005).  The gangliosides of neural tissue have only NANA, not NGNA, 
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linked to their galactose residues (Table 1).  There are over 188 known 
ganglioside structures, with the biodiversity deriving from variations in 
their fatty acid chain length, sugar chain combinations, and sialic acid 
content.  Thus far, there is evidence for their involvement in 
membrane subdomain structure, cell-cell adhesion, signal 
transduction, and myelin stability (Yu et al. 2011, Rosenberg, 
Schengrund 1976, Schnaar 2010, Vyas, Schnaar 2001). 
 Ganglioside biosynthesis takes place in the endoplasmic 
reticulum, while oligosaccharide modifications to the lipid backbone 
take place in the Golgi (Yu et al. 2011, Ichikawa, Hirabayashi 1998).  
The three ceramide metabolizing enzymes are glucosylceramide 
synthase (GluCer synthase or GlcT), sphingomyelin synthase (SM 
synthase) and galactosylceramide synthase (GalCer synthase or GalT-
III) (Ichikawa, Hirabayashi 1998).  The first step of ganglioside 
biosynthesis (GluCer synthesis) takes place on the cytoplasmic side of 
the Golgi, while the subsequent steps take place on the luminal side 
(Maccioni, Giraudo & Daniotti 2002, Ichikawa, Hirabayashi 1998, 
Maccioni, Quiroga & Ferrari 2011). With the exception of GM4, 
Lactosylceramide (LacSer) is the precursor molecule for all 
gangliosides (Figure 2). The asialo, “a”, “b”, and “c” series of 
gangliosides are all synthesized in parallel by a series of 
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oligotransferases and sialyltransferases in a stepwise fashion before 
budding from the Golgi and fusing with the plasma membrane (Yu et 
al. 2011, Sandhoff, van Echten 1994, Yu et al. 2004, Yu, Nakatani & 
Yanagisawa 2009).  
 The sequential degradation of gangliosides follows a similar 
pathway, taking place in the acidic lysosomal compartment.  Plasma 
membrane components containing gangliosides targeted for 
degradation are shuttled through endosomal compartments to the 
lysosomes, where they are broken down into ceramide by a series of 
substrate-specific hydrolases, and deacylated to sphingosine (Kolter, 
Sandhoff 1998, Butters, Dwek & Platt 2005).  Degraded lipids can then 
reenter the biosynthesis pathway, or undergo further degradation.  
The synthesis and degradation of GSLs is tightly controlled during 
development, due to transcriptional modification of oligotransferases 
and lysosomal hydrolases (Maccioni, Giraudo & Daniotti 2002). 
 
Lysosomal Storage Disorders 
 Mutations in the substrate-specific hydrolases of the lysosome, 
or their associated activator proteins, can result in the storage of 
GSLs.  When GSL catabolism cannot keep pace with metabolism, as 
measured by a defined threshold of enzymatic activity (generally < 
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5% of wild type activity), eventually intracellular aggregates of GSL 
will obstruct the normal lipid transport pathways, rapidly accelerating 
GSL storage (Kolter, Sandhoff 1998, Butters, Dwek & Platt 2005).  The 
GM1 and GM2 gangliosidoses belong to a large spectrum of lysosomal 
storage disorders (LSDs) that are a result of metabolic defects in one 
or more GSL catabolizing enzymes. 
 GM1 gangliosidosis is the result of an autosomal recessive 
mutation in β-galactosidase (Figure 3).  Affected individuals are unable 
to hydrolyze the terminal galactose residues of GSLs, resulting in the 
neuronal accumulation of ganglioside GM1 and its asialo derivative, 
GA1.  The phenomenon was first reported in 1959 by Norman et al. 
(Norman et al. 1959).  The genetic nature of the disease was reported 
in 1968 (Okada, O'Brien 1968).  The quantity of GM1 stored, and the 
onset of pathology is inversely related to the enzymatic activity.  
Common symptoms include lysosomal swelling, neuronal apoptosis, 
loss of motor coordination, microgliosis, astrogliosis, ataxia, blindness, 
limb/muscle wasting, organomegaly, demyelination (oligodendrocyte 
loss), and premature death (Baek et al. 2010, Broekman et al. 2007, 
Sano et al. 2009, Brunetti-Pierri, Scaglia 2008, Tessitore et al. 2004, 
Kasama, Taketomi 1986).  There is still no available cure for GM1 
gangliosidosis. 
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 The first report on the GM2 gangliosidoses came in 1881, when 
British ophthalmologist Warren Tay observed a “cherry red spot” in the 
eye of a one year old child that had grown progressively weaker since 
3 months after birth (Squire 2009).  Independently, American 
neurologist Bernard Sachs reported similar findings in 1887.  In 1896, 
Sachs dubbed the phenomenon “amaurotic family idiocy”.  The work of 
Ernst Klenk, Lars Svennerholm, Konrad Sandhoff, Okada and O’Brien, 
and others in the 20th century elucidated the biochemical origin of the 
‘Tay-Sachs’ disease (TSD) to be storage of ganglioside GM2, caused by 
the mutation in one of the β-hexosaminidase subunits (Squire 2009, 
Sandhoff, Andreae & Jatzkewitz 1968, Okada, Veath & O'Brien 1970). 
 GM2 ganglioside is catabolized by the GM2 activator protein and 
β-hexosaminidase A, a protein heterodimer consisting of α and β 
subunits coded by the genes Hexa and Hexb, respectively (Figure 4 
and Figure 5). The GM2 gangliosidoses consist of the O variant 
(Sandhoff Disease, or SD) the B variant (Tay-Sachs disease), and the 
AB variant (GM2 activator protein deficiency).  In Sandhoff disease, a 
mutation in Hexb causes deficiencies in both β-hexosaminidase A and 
the β-hexosaminidase B (ββ homodimer) isoenzymes.  In Tay-Sachs 
disease, a mutation in Hexa causes deficiency in β-hexosaminidase A.  
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In both cases, the “classical” pathway for GM2 ganglioside degradation 
to GM3 is disrupted (Figure 4).  
 
Murine Models of the Gangliosidoses 
Mouse models for the GM1 and GM2 gangliosidoses have been 
developed by homologous recombination and embryonic stem cell 
technology, and are well characterized (Hahn et al. 1997, Yamanaka et 
al. 1994, Phaneuf et al. 1996, Sango et al. 1995).  β-gal -/- mice have 
no β-galactosidase enzymatic activity, and store GM1 and GA1 at early 
ages (Kasperzyk et al. 2004, Kasperzyk et al. 2005).  β-gal -/- mice 
suffer from ataxia, hind-limb wasting, blindness, neuroinflammation, 
neuronal demyelination, and eventually succumb to the disease at 
about 10 months after birth (Baek et al. 2010, Broekman et al. 2007, 
Hahn et al. 1997).  
 Mouse models of Sandhoff disease (Hexb-/-) exhibit more severe 
pathology than the GM1 mouse, displaying symptoms at about 100 
days and rapidly progressing to a moribund state by 125 days (Denny 
et al. 2010, Denny et al. 2006).  It has also recently been reported 
that Hexb-/- mice suffer from thymic shrinkage at 14 weeks (Matsuoka 
et al. 2011).  Because of the “alternative” pathway of GM2 catabolism 
that exists due to murine sialidase activity (Figure 4), Hexa-/- (Tay-
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Sachs Disease) mice do not display overt phenotypic symptoms even 
at adult ages, despite storing GM2 ganglioside (Sango et al. 1995). 
 
Feline Models of the Gangliosidoses 
 Natural animal models for the gangliosidoses exist in cats, dogs, 
sheep, flamingos, bears, and a variety of other large animal models 
(Zeng et al. 2008, Yamato et al. 2004, Yamato et al. 2008, Satoh et 
al. 2004, Torres et al. 2010).  Because the surface area, complexity, 
and neuron number of the brain increases in larger animal models, 
they represent a difficult but necessary intermediate for therapies 
intended for clinical use (Baek et al. 2009b).  As the final part of my 
dissertation, we have had the chance to examine tissue from an 
established feline model for Sandhoff disease (Cork, Munnell & Lorenz 
1978, Martin et al. 2004). 
 
 During my research, we examined several therapeutic 
approaches to alleviating the GM1 and GM2 (SD & TSD) gangliosidoses 
in murine and feline models.  We discovered that the cholesterol-
detecting molecule, filipin, might provide misinformation in ganglioside 
storage disorders, as it can bind to aggregating ganglioside GM1.  We 
found that substrate reduction was more effective than cross-
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corrective therapy in correcting juvenile ganglioside storage.  Finally, 
we found that gene therapy utilizing Adeno-associated viral vectors 
was profoundly effective at clearing storage and reducing pathology in 
adult mice and cats.    
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Figure 1. The structure and membrane orientation of ganglioside GM2.  
The hydrophobic ceramide moiety anchors the molecule to the outer 
leaflet of neuronal plasma membranes.  The hydrophilic 
oligosaccharide chain extends into the extracellular space and plays a 
role in the biodiversity and function of gangliosides.  Adapted from 
themedicalbiochemistrypage.org. 
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Figure 2. Ganglioside and GSL biosynthesis pathways.  The 
nomenclature for gangliosides are based on those of Lars Svennerholm 
(Svennerholm 1963) and are explained in Table 1.  Adapted from Yu et 
al (Yu et al. 2011, Yu et al. 2004).  Cer, Ceramide; GalT, 
Galactosyltransferase; ST, Sialyltransferase; GlcT, 
Glucosyltransferase; GalNacT, N-acetylgalactosaminyltransferase. 
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Figure 3. GM1 gangliosidosis.  The loss of β-galactosidase enzyme 
activity prevents the hydrolysis of GM1 to GM2.  Adapted from 
Brunetti-Perri and Scaglia (Brunetti-Pierri, Scaglia 2008). 
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Figure 4. Catabolic breakdown of GM2 ganglioside.  In the “classical” 
pathway, GM2 ganglioside is hydrolyzed to GM3 by Hex A (αβ 
heterodimer) and the GM2 activator protein (GM2 AP).  Sialic acid is 
then removed from GM3 to yield Lactosylceramide. In the “alternative” 
pathway, which is more prevalent in mice than in humans, sialidase 
converts GM2 to GA2, which is then hydrolyzed by either Hex A or Hex 
B (ββ homodimer) to yield LacCer. Adapted from Sango et al. (Sango 
et al. 1995).   
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Figure 5. Hydrolysis of ganglioside GM2 by the GM2 activator protein 
and β-hexosaminidase A (Hex A). Hex A, a heterodimer consisting of α 
and β subunits, can only access the sugar moieties of gangliosides 
when they are in aqueous phase.  The GM2 activator protein is 
necessary to lift the GM2 ganglioside out of the lysosomal membrane. 
Kolter and Sandhoff (Kolter and Sandhoff 2005).   
  
  19 
  
  20 
CHAPTER TWO 
Filipin recognizes both GM1 and cholesterol in GM1 gangliosidosis 
mouse brain 
 
INTRODUCTION 
Filipin, a fluorescent marker for cholesterol 
Filipin is a polyene antifungal antibiotic produced naturally by the 
bacteria Streptomyces filipinensis (Whitfield et al. 1955, Ammann, 
Gottlieb 1955, Brock 1956) (Figure 6).  Early reports showed that 
filipin disrupted permeability of sterol-containing membranes in 
Neurospora crassa causing cellular leakage (Kinsky 1961, Gimpl, 
Gehrig-Burger 2007).  Due to its fluorescence shift upon binding to 
cholesterol, filipin is visible under simple UV trans-illumination 
(Schroeder, Holland & Bieber 1971, Norman et al. 1972).  This 
property has made filipin a histochemical marker for unesterified 
cholesterol in numerous diseases including Niemann-Pick Type C (NPC) 
(Harzer, Kustermann-Kuhn 2001, te Vruchte et al. 2004, Pham et al. 
2005), Alzheimer’s Disease (AD) (Yanagisawa 2003), GM1 
gangliosidosis (Broekman et al. 2007), and Huntington’s disease 
(Trushina et al. 2004).  Filipin has also been used extensively as a 
marker of cholesterol trafficking in subcellular membranes (Puri et al. 
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1999, Smejkal, Hoppe & Hoff 1996, Hoppe et al. 1997).  Although 
most citations (about 1000) to filipin in PubMed involve cholesterol 
binding, the specificity of the binding remains highly speculative 
(Gimpl, Gehrig-Burger 2007).  It is thought to bind to cholesterol with 
1:1 stoichiometry, forming aggregrates in the center of the lipid 
bilayer (Richardson, Rychnovsky 1996). 
 
Filipin in GM1 Gangliosidosis 
Filipin fluorescence was previously reported in fibroblasts and in 
brain tissue from a murine model of GM1 gangliosidosis (Broekman et 
al. 2007, Pham et al. 2005, Puri et al. 1999).  These findings 
suggested that cholesterol was a secondary storage molecule to GM1 
in this disease.  GM1 gangliosidosis is an autosomal recessive 
glycosphingolipid (GSL) storage disorder caused by mutations in 
lysosomal β-galactosidase activity (Brunetti-Pierri, Scaglia 2008, 
Kasperzyk et al. 2004, Norden, O'Brien 1975).  The loss or reduction 
of β-galactosidase activity results in a failure to cleave the terminal 
galactosyl residue of ganglioside GM1 leading to excessive CNS 
storage of GM1 and its asialo derivative, GA1 (Sano et al. 2009, 
Tessitore et al. 2004, Kasperzyk et al. 2005, Hauser et al. 2004, 
d'Azzo, Tessitore & Sano 2006).  Secondary storage materials are not 
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uncommon in some lipid storage disorders (Watanabe et al. 1998, 
Walkley 2004, McGlynn, Dobrenis & Walkley 2004, Xu et al. 2010).  
The presence of excess sphingolipid (sphingomyelin or 
lactosylceramide) alone is sufficient to induce cholesterol 
internalization and “trapping” (Puri et al. 2003, Glaros et al. 2005).  
The internalization of cholesterol in NPC1 knockout cells is dependent 
on the presence of ganglioside GM3 (Gondre-Lewis, McGlynn & 
Walkley 2003).  While abnormal cholesterol trafficking can be 
visualized in many lipid storage disorders, the co-localization of 
cholesterol and other storage materials is not clear (McGlynn, Dobrenis 
& Walkley 2004, Jeyakumar et al. 2005).  The lipid raft hypothesis 
suggests that cholesterol and GM1 are organized with transmembrane 
proteins in distinct raft domains (Simons, Gruenberg 2000, Kaiser et 
al. 2009), providing a model for extensive GM1/cholesterol co-
localization seen in normal and disease states. 
We previously described filipin-positive staining in brain tissue of 
β-galactosidase (β-gal) knockout (-/-) mice suggesting that cholesterol 
and GM1 were co-localized in lysosomes (Broekman et al. 2007).  
Moreover, β-galactosidase gene therapy lessened or completely 
abrogated GM1 and GA1 ganglioside storage and filipin staining. 
However, the quantification of unesterified cholesterol showed no 
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abnormal storage in the brains of β-gal-/- mice.  No change in 
cholesterol content was observed after treatment with AAV gene 
therapy, which reduced ganglioside storage (Broekman et al. 2007).  If 
filipin staining is a reliable marker for membrane cholesterol content, 
then changes in filipin staining should correlate with measurable 
changes in the content of membrane cholesterol.  
Here we sought to test the hypothesis that GM1 ganglioside 
storage disrupts cholesterol localization within the plasma membrane 
and microsomes of GM1 gangliosidosis mouse brain. We found that 
even amongst sub-cellular (microsomal) fractions enriched in GM1 and 
GA1, there was no significant corresponding increase in unesterified 
cholesterol content.  Furthermore, we found that filipin, which was 
reported previously to bind weakly to phospholipids (Smejkal, Hoppe & 
Hoff 1996), also binds gangliosides, especially GM1.  These findings 
indicate that the filipin-positive staining seen in GM1 gangliosidosis 
mouse brain cannot be solely attributed to an increase in intracellular 
cholesterol.  
 
MATERIALS AND METHODS 
Mice  
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B6/129Sv mice, heterozygous for the GM1 β-galactosidase gene (βgal 
+/-) were obtained from Dr. Alessandra d’Azzo of Saint Jude Children’s 
Research Hospital, Nashville, TN.  These mice were derived by 
homologous recombination and embryonic stem cell technology as 
previously described (Hahn et al. 1997).  Homozygous β-gal (-/-) 
mouse pups were derived from crossing β-gal (-/+) females with β-gal 
(-/-) male mice.  Genotypes were determined by measuring β-
galactosidase specific activity in tail tissue using a modification of the 
Galjaard procedure (Hauser et al. 2004, Galjaard 1979).  All mice were 
propagated in the Boston College Animal Care Facility and were 
housed in plastic cages with filter tops containing Sani-Chip bedding 
(P.J. Murphy Forest Products Corp., Montville, NJ).  The room was 
maintained at 22 ˚C on a 12h light – 12h dark cycle.  Food (PROLAB 
R/M/H/ 3000 Lab Chow, Agway, St. Louis, MO) and water were 
provided ad libitum.  Nursing females were provided with cotton 
nesting pads for the duration of the experiment.  All animal 
experiments were carried out with ethical committee approval in 
accordance with the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals and were approved by the Institutional 
Animal Care Committee. 
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Brain subcellular fractions  
Mice were sacrificed by cervical dislocation and excised brain tissue 
was immediately frozen for analysis.  The procedure of Lomnitski et al 
(Lomnitski et al. 1999) was used to prepare brain subcellular fractions. 
Briefly, whole brains were homogenized in 4 mL of centrifugation 
solution (1 µg/µl Aprotinin (Sigma Aldrich, St. Louis, MO), 1 mM 
phenyl methyl sulfonyl fluoride (PMSF), 1mM EDTA in 50 mM 
potassium phosphate buffer).  The homogenates were transferred to 5 
mL polyallomer centrifuge tubes (Beckman, Palo Alto, CA) and 
centrifuged for 10 min at 1,000 x g (4°C).  The P1 (nuclear membrane) 
pellet was separated from the subsequent supernatant.  The 
supernatant was collected and centrifuged again at 10,000 x g (4°C), 
resulting in a P2 pellet enriched in plasma membrane and 
mitochondria.  The supernatant was further centrifuged for 1 hr at 
150,000 x g (4°C), resulting in a P3 pellet enriched in microsomes.  
Both the P2 and the P3 pellets for all samples were suspended in 1 ml 
dH2O. A 500 µl aliquot of the whole brain homogenate was collected 
before the first spin. From each whole brain homogenate, P2 Plasma 
Membrane (PM) pellet suspension, and P3 Microsomal (MS) pellet 
suspension from β-gal -/- and β-gal +/- mice, half of each homogenate 
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was assayed for protein content, while the other half was used for the 
isolation and purification of lipids. 
 
Protein quantification   
Protein content from whole brain and individual membrane fractions 
were quantified using a Bio-Rad DC Protein Assay Kit (Bio-Rad, 
Hercules, CA).  Serial 1:10 and 1:20 dilutions of each sample were 
aliquoted onto a Corning 96-well clear assay plate in triplicate.  After 
adding the assay reagents, samples were incubated at room 
temperature for 15 min, and then read at 750 nm on an M5 
SpectraMax Microplate Reader (Molecular Devices, Sunnyvale, CA).  
Protein concentrations were determined by fitting the samples to a 
standard curve using bovine serum albumin (BSA). 
 
Western blotting   
The distribution of calnexin, an endoplasmic reticulum marker (Kiebish 
et al. 2008), among the subcellular fractions was determined by 
Western Blot. Protein concentrations of cell fractions were estimated 
using the Bio-Rad DC protein assay as described above. 18 mg of total 
protein from each sample was loaded onto a 4-12% sodium dodecyl 
polyacrylamide gel (Invitrogen, Carlsbad, CA) and separated by 
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electrophoresis. Gels were run for 30 minutes at 100 volts, then 50 
minutes at 150 volts. Proteins were transferred for 16 hours at 30 
volts to a polyvinylidene difluoride Immobilon-P membrane (Millipore, 
Billerica, MA). The membrane was blocked in 5% blotting grade 
blocker non-fat dry milk (Bio-Rad, Hercules, CA) in 1x Tris-buffered 
saline with Tween 20 (TBS-T) for 3 hours at room temperature. Blots 
were washed in TBS-T three times for 5 minutes each, and then 
probed for 16 hours at 4oC with primary antibodies against calnexin 
(Millipore, Billerica, MA), diluted 1:750, and β-actin (Cell Signaling, 
Danvers, MA), diluted 1:4000.  Blots were washed again with TBS-T 
three times for 15 minutes, and then probed for 90 minutes at room 
temperature with secondary antibodies against mouse (Santa Cruz 
Biotechnology, Santa Cruz, CA), diluted 1:4000, and rabbit (Cell 
Signaling, Danvers, MA), diluted 1:4000.  Protein bands were 
visualized with Pierce ECL western blotting substrate (Fisher Scientific, 
Houston, TX). 
 
Total lipid isolation   
Total lipids were isolated and purified from cerebral cortex as 
previously described (Kasperzyk et al. 2004, Hauser et al. 2004).  
Frozen cortex samples were homogenized in centrifugation solution, 
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separated into fractions as described above, and lyophilized for 24 hr. 
After desiccation, the dried tissue was weighed, resuspended in water, 
and lipids were extracted overnight in CHCl3: CH3OH 1:1.  Lipids were 
further separated into a neutral (F1) and acidic/ganglioside (F2) 
fraction via ion exchange chromatography over a Sephadex column.  
Neutral lipids (phosphatidylcholine, phosphatidylethanolamine, 
plasmalogens, ceramide, sphingomyelin, cerebrosides, and GA1) and 
cholesterol were eluted with CHCl3 : CH3OH : dH20 (30 : 60 : 8, v:v:v). 
Acidic phospholipids and gangliosides (including GM1) were eluted with 
CHCl3 : CH3OH : 0.8M C2H3NaO2 (30 : 60 : 8, v:v:v).   
 
Sialic acid quantification  
Gangliosides were further separated from acidic phospholipids and 
desalted as previously described (Kasperzyk et al. 2004, Hauser et al. 
2004).  Total ganglioside content was quantified before and after 
desalting using the resorcinol assay.  Three aliquots of each 
ganglioside sample were dried under vacuum.  A resorcinol:dH20 1:1 
v:v solution (Resorcinol Reagent – HCl : 0.2M Resorcinol : dH20 : 0.1M 
CuSO4, 40 : 5 : 5 : 0.125, v:v:v:v) was added to each sample, 
followed by submersion in a boiling water bath for 17 min.  After 
cooling on ice, the reaction was stopped with butyl acetate:N-butanol 
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85:15 v:v.  Each sample was vortexed and centrifuged at 700 x g for 2 
min.  The absorbance of the upper aqueous layer was recorded at 580 
nm using a Shimadzu UV-1601 Spectrophotometer (Shimadzu, 
Torrance, CA).  Sialic acid values were fit to a standard curve using N-
acetylneuraminic acid as a standard.   
 
High Performance Thin Layer Chromatography   
Lipids were spotted on 10 x 20 cm Silica gel 60 HPTLC plates using a 
Camag Linomat III auto-TLC spotter (Camag Scientific Inc., 
Wilmington, NC) as previously described (Kasperzyk et al. 2004, 
Hauser et al. 2004, Macala, Yu & Ando 1983). The amount of lipid per 
lane was equivalent to 1.5 µg sialic acid for gangliosides, and 10 µg of 
protein for neutral lipids/cholesterol.  Gangliosides were separated by 
a single ascending run (90 min) in a solution of CHCl3:CH3OH:0.02% 
CaCl2 (55:45:10, v:v:v), while neutral lipids/cholesterol were 
separated by an initial ascending run (up to 4.5 cm) with a solution of 
CHCl3:CH3OH:acetic acid:formic acid:dH20 (35 : 15 : 6 : 2 : 1, 
v:v:v:v:v), dried for 15 minutes, and then run to the top with 
hexanes:diisopropyl ether:acetic acid (65 : 35 : 2, v:v:v) (Fisher 
Scientific, Houston, TX).  Gangliosides were visualized by spraying the 
dried plates with the resorcinol reagent, followed by heating at 95°C.  
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Neutral lipids and cholesterol were visualized by dipping the dried 
plates in 3% cupric acetate in an 8% phosphoric acid solution, followed 
by heating the plate to 140°C (40). 
 
GM1 and cholesterol quantification  
A Personal Densitometer SI with ImageQuant software (Molecular 
Dynamics, Sunnyvale, CA, USA) was used to estimate the 
concentrations of gangliosides and cholesterol on HPTLC.  The total 
ganglioside content was normalized to 100%, and the percent 
distribution of each band was used to determine the sialic acid 
concentration for individual gangliosides.  GM1 content was expressed 
as µg/mg protein.  For neutral plates, the band density values for 
cholesterol in each sample lane (equivalent to 10 µg of protein) was fit 
to a standard curve, and used to determine cholesterol concentration 
expressed as µg/mg protein. 
 
Filipin UV visualization  
Purified GM1 and cholesterol (from mouse brain) were successively 
spotted with increasing nmol amounts on an HPTLC plate and 
separated by the neutral solvent systems described above. For UV 
visualization of whole brain homogenates and subcellular fractions, the 
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equivalent of 20 mg of protein was spotted for both neutral lipids and 
gangliosides. HPTLC plates were sprayed with a solution of filipin-PBS 
(6.0 mg filipin complex dissolved in 300 ml dimethyl formamide 
(Sigma Aldrich, St. Louis, MO), added to 49.7 ml PBS).  The filipin-
stained plates were shielded from light and placed in a Shel Lab 
General laboratory incubator (Sheldon Manufacturing, Cornelius, OR) 
at 37°C for 90 min.  The plates were then washed 3x in dH20, and 
visualized via UV transillumination as previously described (Smejkal, 
Hoppe & Hoff 1996).  UV fluorescence at 365 nm was determined 
using a Camag TLC scanner 4 (Camag Scientific Inc., Wilmington, NC) 
with winCATS software.  After UV visualization, gangliosides were 
visualized by spraying the dried plate with the resorcinol reagent and 
heating at 95°C.  Cholesterol was visualized by dipping the dried plate 
in 3% cupric acetate in an 8% phosphoric acid solution, followed by 
heating the plate to 140°C as described above (Macala, Yu & Ando 
1983).  
 
RESULTS 
Ganglioside and lipid content in subcellular fractions 
In order to determine if the fluorescence from filipin complex 
corresponded to cholesterol content, we evaluated the content and 
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distribution of lipids in whole brain and in subcellular fractions from 
15-week old normal (β-gal +/-) and GM1 gangliosidosis (β-gal -/-) 
mice. Calnexin, an ER marker, was enriched in the microsomal fraction 
compared to whole brain and plasma membrane (Figure 7). No 
significant differences were found between the +/- and -/- mice for 
brain weight or protein content in plasma membranes or microsomes 
(Table 2).  The total sialic acid content in β-gal -/- mouse brain was 
significantly higher than in normal mouse brain (Table 2).  Sialic acid 
concentration (µg/mg protein) was similar in microsomes and plasma 
membrane of +/- mice (Table 2).  Total sialic acid content for -/- mice 
was 2-fold greater, 3-fold greater, and 7-fold greater in whole brain, 
plasma membrane, and microsomal fractions, respectively, compared 
to +/- mice (Table 2).  Most of the increase in total SA concentration 
in the -/- mice was due to an increase in GM1 content (Figure 8).  GM1 
content was 50-fold greater in the microsomes of -/- mice than in +/- 
mice (Figure 8, Table 2). 
The HPTLC of the neutral lipids shows that 
phosphatidylethanolamine (PE) was the major neutral phospholipid of 
the plasma membrane fraction, whereas phosphatidylcholine (PC) was 
the major neutral phospholipid of the microsomal membrane fraction 
(Figure 9).  Asialo GM1 (GA1) accumulated in β-gal -/- mouse brain, 
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with the greatest concentration found in the MS fraction (Figure 9).  
No significant differences were found in cholesterol content between 
+/- and -/- mice in whole brain, plasma membrane, or microsomes 
(Table 2).  
To quantitatively assess the fluorescent reactivity of filipin, we 
spotted HPTLC plates with equivalent nmol amounts of both 
cholesterol and ganglioside GM1 from mouse brain.  Cholesterol 
exhibited strong UV fluorescence (Area Units/nmol) as expected when 
incubated with filipin complex on HPTLC (Figure 10A).  A best fit line 
revealed a linear correlation between nmol cholesterol content and 
detectable fluorescence (Figure 10B); no quenching was observed at 
the concentrations measured (Smejkal, Hoppe & Hoff 1996, Beknke, 
Tranum-Jensen & van Deurs 1984). We found that GM1 ganglioside 
also elicited detectable fluorescence with the filipin complex after a 90 
min incubation (Figure 10A).  UV fluorescence also increased 
corresponding with a linear increase in GM1 content at higher nmol 
amounts (Figure 10B).  Notably, the fluorescence observed from 
filipin/GM1 binding was equal to or greater than the florescence 
observed from filipin/cholesterol binding (Figure 10B).   
To determine if our lipid quantification corresponded with 
fluorescence, we applied filipin to HPTLC of neutral lipids and 
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gangliosides isolated from the subcellular fractions in β-gal +/- and β-
gal -/- mouse brain. Cholesterol and phosphatidylcholine were both 
visible by UV transillumination after incubation with filipin in the 
neutral lipids purified from microsomal fractions of +/- mice (Figure 
11A).  GA1, cholesterol, and phosphatidylcholine were detectable in 
microsomal fractions of -/- mice (Figure 11A). There was no difference 
in the fluorescent signal (Area units/mg protein) of cholesterol in 
microsomal fractions in -/- and +/- mice (Figure 11A, Table 3).  There 
was no detectable fluorescent signal from the microsomal gangliosides 
of +/- mice. (Figure 11B, Table 3).   Conversely, there was a 
prominent fluorescent signal corresponding to GM1 in the microsomal 
gangliosides of -/- mice (Figure 11B, Table 3). 
 
DISCUSSION 
Using filipin as a cholesterol marker, Broekman et al showed that 
GM1 accumulation was accompanied by strong filipin staining in 
lysosomal membranes (Broekman et al. 2007).  These findings 
suggested that cholesterol accumulated in lysosomes along with GM1.  
In this study we showed that GM1 accumulation was not associated 
with significant increases of cholesterol content in microsomal 
membranes.  Our findings raise concerns in using filipin as an accurate 
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marker for quantitative cholesterol content in GM1 gangliosidosis 
brain.  The cholesterol trapping hypothesis proposes that the 
accumulation of one type of lipid raft molecule in late endosomes will 
lead to an accumulation of other types of raft lipids, eventually 
impeding raft lipid turnover and cholesterol trafficking (Simons, 
Gruenberg 2000).  If GM1 and cholesterol were tightly associated in 
raft lipids, it follows that the accumulation of GM1 should directly 
cause the accumulation of cholesterol.  However, our biochemical lipid 
analysis showed that GM1 accumulation alone was capable of 
producing a filipin-positive signal in the brain of β-gal -/- mice.  We did 
not quantify cholesterol in lysosomes specifically in this study, but the 
presumed co-localization of GM1 would overstate the presence of 
cholesterol in any lipid sub-domain examined.  
Although filipin binding is greater for cholesterol than for 
phosphatidylcholine on HPTLC, filipin was considered somewhat 
promiscuous in its lipid binding capabilities (Smejkal, Hoppe & Hoff 
1996).  Our data suggest that the promiscuity of the filipin complex 
can also extend to gangliosides.  Our findings also suggest that 
accumulation of GM1 can produce misinformation on cholesterol 
content when filipin is used as a cholesterol marker. This is an obvious 
caveat for using filipin as a histochemical marker for known lysosomal 
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storage disorders, as gangliosides can accumulate as either primary or 
secondary storage material in several storage diseases (Watanabe et 
al. 1998, Walkley 2004, McGlynn, Dobrenis & Walkley 2004, Xu et al. 
2010, Brante 1952, Heinecke et al. 2011). 
Our findings might help resolve several inconsistencies 
associated with storage of cholesterol and gangliosides seen in the 
GM1 gangliosidosis and Niemann-Pick Type C disease.  For example, 
cyclodextrin treatment abrogates filipin signal and corrects cholesterol 
storage in NPC1 fibroblasts and mouse models (Davidson et al. 2009, 
Abi-Mosleh et al. 2009, Liu et al. 2010).  However, cyclodextrin has no 
effect on filipin signal in GM1 gangliosidosis fibroblasts or mouse tissue 
(Davidson et al. 2009).  Earlier studies in human GM1 gangliosidosis 
brain showed a decrease in cholesterol content depending on the 
severity of the disease (Kasama, Taketomi 1986).  Filipin also inhibits 
the internalization of the Vibrio cholorae cholera toxin, which avidly 
binds to GM1 (Orlandi, Fishman 1998, Sugimoto et al. 2001).  This 
finding further suggests a cross-reactivity of filipin with GM1. 
We did not attempt to evaluate membrane fractions based on 
their detergent-resistant properties.  The analysis of GM1 and 
cholesterol in detergent resistant membranes or lipid rafts holds the 
caveat that different raft preparations can produce disparate results 
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(Mellgren 2008, Adam et al. 2008).  The membrane fractionation 
performed here yielded results consistent with previous findings 
regarding ganglioside GM1 and asialo GA1 storage in late endosomes 
of β-gal -/- mice (Puri et al. 2003).  We also confirmed the previous 
findings of Lomnitski and co-workers that phosphatidylethanolamine 
and phosphatidylcholine are enriched in plasma membranes and 
microsomes, respectively (Lomnitski et al. 1999).  While the P2 
fractions examined here did contain mitochondria, we have previously 
demonstrated that purified mitochondria from normal mouse brain 
contain only trace amounts of detectable ganglioside (Kiebish et al. 
2008). Further, a report from Sano et al showed that the GM1 storage 
seen in mitochondrial preparations from GM1 gangliosidosis mouse 
brain is primarily due to its presence in mitochondria-associated ER 
membranes (Sano et al. 2009).  We conclude that the appearance of 
filipin-positive staining in tissues from GM1 gangliosidosis results from 
the cross reactivity of filipin with GM1 ganglioside in addition to 
binding of filipin with cholesterol.  While our findings should not 
decrease the utility of filipin as a histochemical marker for non-
esterified cholesterol, they do question the specificity of filipin as a 
marker solely for cholesterol in certain disease conditions.  
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Figure 6. The Structure of Filipin III.  Filipin III is the primary 
component of the Filipin complex (53%), with I (4%), II (25%), and 
IV (18%) being closely related isoforms.  Adapted from Bergy et al. 
and Richardson et al. (Bergy, Eble 1968, Richardson, Rychnovsky 
1996). 
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Figure 7. Calnexin is enriched in P3 (microsomal) fractions of normal 
and GM1 gangliosidosis mouse brain. Equivalent protein aliquots from 
each subcellular fraction were separated by electrophoresis, 
transferred to immobilon-P membranes, and incubated with antibodies 
against calnexin (upper bands) and β-actin (lower bands).   
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Figure 8. High Performance Thin Layer Chromatography of 
gangliosides in subcellular fractions of GM1 brain. Gangliosides were 
isolated and purified for each fraction from control (β-gal +/-) and 
GM1 gangliosidosis (β-gal -/-) mouse brains. 1.5 µg of sialic were 
spotted per lane.  Quantification of GM1 content is displayed in Table 
2. 
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Figure 9. HPTLC of cholesterol and neutral lipids in GM1 brain 
fractions. Neutral phospholipids and cholesterol were isolated and 
purified for each fraction from control (β-gal +/-) and GM1 
gangliosidosis (β-gal -/-) mouse brains. The equivalent of 10 mg of 
protein was spotted for each neutral lipid sample.  Notably, asialo GM1 
(GA1) is enriched in the microsomal fraction of the β-gal -/- mouse 
brain.  Quantification of cholesterol content is displayed in Table 2. 
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Genotype Fraction
Whole Brain 403 ± 20 5.9 ± 0.1 3.8 ± 0.2 0.5 ± 0.1 85 ± 38
!-gal+/- P2 2.4 ± 0.4 7.8 ± 0.3 0.7 ± 0.1 131 ± 16
P3 0.7 ± 0.2 7.4 ± 0.9 1.0 ± 0.1 117 ± 30
Whole Brain 414 ± 4 6.0 ± 0.1 7.8 ± 0.3e 5.2 ± 0.2e 80 ± 9
!-gal-/- P2 2.7 ± 0.1 22.4 ± 0.7e 17.0 ± 0.7e 150 ± 15
P3 1.2 ± 0.2 52.5 ± 4.4e 49.0 ± 4.0e 163 ± 18
TABLE 2: Protein, Cholesterol, and Ganglioside content in Subcellar Fractions of GM1 Gangliosidosis Mouse Brain
Cholesterold 
(ug/mg protein)
Values are expressed as the mean ± standard error of the mean. N = 3 mice per group.
d Cholesterol content was determined through densitometric scanning of HPTLC plates as seen in Figure 8.
Wet Weight 
(mg)
a Protein values were determined using the Biorad assay as described in Methods.                                                                                                                               
b Sialic acid values were determined using the resorcinol assay as described in Methods.
c GM1 content was determined through densitometric scanning of HPTLC plates as seen in Figure 7.
GM1c (µg sialic 
acid/mg 
protein)
e Significantly different from the !-gal+/- value in the same fraction at  P < 0.01 using a student's t-test.
Proteina 
(mg/ml)
Sialic Acidb 
(µg/mg protein)
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Figure 10. Filipin complex binds to ganglioside GM1 on HPTLC. HPTLC 
plates containing equivalent nmol amounts of unesterified cholesterol 
and GM1 ganglioside were separated by dual solvent systems and 
incubated with filipin complex for 90 min.  A) UV transillumination 
revealed reactivity with both lipids.  The resorcinol reagent 
subsequently confirmed the presence of GM1. B) Quantitation of UV 
fluorescence at 365 nm.  R2 values suggest a linear correlation 
between the nmol of GM1 or cholesterol with filipin fluorescent 
detection. 
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Figure 11. Filipin reactivity with P3 (microsomal) phospholipids, 
cholesterol, and gangliosides. Equivalent (20 mg) protein aliquots from 
the isolated neutral lipid (A) or ganglioside (B) microsomal fractions of 
control (β-gal +/-) and GM1 gangliosidosis (β-gal -/-) mouse brains 
were spotted on HPTLC, separated with the appropriate solvent 
system, and incubated with filipin complex for 90 min. A) The primary 
filipin-positive bands in the neutral lipid microsomes are cholesterol 
(chol) and phosphatidylcholine (PC).  GA1 is detectable in the β-gal -/- 
microsomal fraction.  B) GM1 is the only detectable band among the 
gangliosides of β-gal -/- mice.  No fluorescent signal is detected in 
control β-gal +/- microsomes.  Cholesterol and GM1 relative 
fluorescence is displayed in Table 3. 
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Genotype
!-gal+/- NDb 954 ± 67
!-gal-/- 1117 ± 75 899 ± 81
Fluoresencea (Area Units/mg protein)
Table 3: Relative UV Fluorescence of GM1 and Cholesterol in 
Microsomal Fractions
GM1 Cholesterol
b ND, no detectable fluorescence.
Values are expressed as the mean ± standard error of the 
mean (SEM).  N = 3 mice per group.
a Relative fluorescence at 365 nm was determined using a 
CAMAG TLC scanner on HPTLC plates as seen in Figure 10.   
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CHAPTER THREE 
Therapeutic Effects of Stem Cells and Substrate Reduction in Juvenile 
Sandhoff Mice 
 
INTRODUCTION 
Lysosomal enzyme cross-correction 
Lysosomal enzymes are synthesized in the endoplasmic 
reticulum, where they undergo glycosylation at select asparagine 
residues (Kornfeld, 1992; Dahms, 1993; Sands and Davidson, 2006). 
Upon reaching the Golgi, they are phosphorylated and bound to the 
mannose-6-phosphate/IGF II receptor (Man-6-P/IGF-IIr).  Once they 
are shuttled via clathrin-coated vesicles to the endosomal/pre-
lysosomal compartments, the acidic pH disassociates the 
protein/receptor complex.  The receptor is either shuttled to the 
plasma membrane or returned to the Golgi.  Approximately 90% of the 
active enzyme remains in the lysosome, with another 10% being 
secreted into the extracellular space.  This extracellular protein can 
then bind to the plasma membrane-bound Man-6-P/IGF-IIr of 
neighboring cells, and after internalization the protein will be targeted 
to late endosomal/lysosomal compartments of the receptor cells.  This 
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protein “sharing” pathway is the basis for enzymatic cross-correction 
therapy (Figure 12). 
 
Combinational Therapy in Murine Sandhoff Disease 
Sandhoff Disease is a lysosomal storage disorder (LSD) caused 
by an autosomal recessive mutation in the beta subunit of β-
hexosaminidase.  Ganglioside GM2, normally hydrolyzed by 
Hexosaminidase A and the GM2 activator protein, accumulates in the 
cells of effected individuals.  In the CNS of Hexb-/- mice, this 
accumulation causes neuronal apoptosis and demyelination, leading to 
cognitive and motor disorders, ataxia, inflammation, and premature 
death (Jeyakumar et al. 2002, Jeyakumar et al. 2003, Kyrkanides et 
al. 2008).  Elevated levels of GM2 and GA2 are detectable as early as 
post-natal day 2 (Baek et al. 2008), with a rapid decline in motor 
performance at 12 weeks after birth, followed by premature death at 
16 weeks (Sango et al. 1995, Phaneuf et al. 1996). 
 Substrate reduction therapy (SRT) utilizing N-alkylated imino 
sugars N-butyldeoxynojirimycin (NB-DNJ) or N-butylgalactonojirimycin 
(NB-DGJ) reduces global ganglioside biosynthesis in the GM1 and GM2 
gangliosidoses, delaying symptom onset and extending longevity by 
lowering the load of stored lipid (Platt et al. 1997, Jeyakumar et al. 
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1999, Ranes et al. 2001, Jeyakumar et al. 2003, Platt et al. 2003, 
Andersson et al. 2004, Kasperzyk et al. 2004, Kasperzyk et al. 2005, 
Platt et al. 2005, Denny et al. 2006, Baek et al. 2008, Elliot-Smith et 
al. 2008, Platt, Jeyakumar 2008, Wortmann et al. 2009, Denny et al. 
2010).  These imino sugars block synthesis of glycosphingolipids by 
inhibiting the action of a ceramide specific glucosyltransferase, GluCer 
synthase (Andersson et al. 2000, Ichikawa, Hirabayashi 1998) (Figure 
13). NB-DNJ is approved for human trials in Gaucher’s disease (Platt et 
al. 2001, Cox et al. 2003). NB-DGJ has similar specificity as NB-DNJ 
but with less adverse side effects at therapeutic doses (Andersson et 
al. 2000). 
 SRT has been used in conjunction with other therapies in order 
to synergistically improve survival in the murine model of Sandhoff 
Disease.  Nonsteroidal anti-inflammatory drugs (NSAIDs) and 
antioxidants reduce microglial activation, oxidative stress, and 
proinflammatory cytokine expression in Sandhoff mouse brain 
(Jeyakumar et al. 2004).  When used together with NB-DNJ, these 
drugs significantly slowed disease progression and increased lifespan 
beyond each monotherapy (Jeyakumar et al. 2004).  Bone marrow 
transplantation (BMT) increases β-hexosaminidase enzyme activity in 
brain, spinal cord, and peripheral tissues of Sandhoff mice (Jeyakumar 
  56 
et al. 2001).  This enzyme replacement therapy further extended the 
lifespan of NB-DNJ treated Sandhoff mice, but without reducing stored 
GM2 and GA2 at the experimental endpoint (Jeyakumar et al. 2001).  
Caloric restriction reduces neural inflammation and improves motor 
performance in Sandhoff mice without altering ganglioside content or 
distribution (Denny et al. 2006).  When NB-DNJ was used in 
conjunction with a calorie restricted ketogenic diet (KD-R), 3.5-fold 
more drug was detected in the forebrain of SD mice compared to the 
standard diet fed group (Denny et al. 2010).  Total sialic acid and GM2 
content was further reduced in the KD-R + NB-DNJ treated group, 
suggesting an additive interaction between the two therapies. 
More recently, intracranial transplantations of murine Neural 
Stem Cells (mNSCs) have been used in neonatal and adult Sandhoff 
mouse models (Lee et al. 2007, Jeyakumar et al. 2009).  In both 
cases, mNSCs migrated to areas of CNS pathology, differentiated into 
stable neurons, delayed symptom onset, decreased inflammatory 
markers, restored a therapeutic level of β-hexosaminidase enzyme 
activity, and lowered stored GM2 and GA2.   Administration of NB-DNJ 
or NB-DGJ to mNSC-treated adult Sandhoff mice reduced GM2 and 
GA2 storage by 50% compared to NSCs alone, contributing to a robust 
increase in lifespan (Lee et al. 2007).  Substrate reduction was also 
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shown to synergistically improve glycolipid clearance when used in 
conjunction with enzyme replacement therapy in a Fabry disease 
mouse model (Marshall et al. 2010). 
 Ganglioside biosynthesis plays an important role in neuronal 
development in neonatal mice (Takamiya et al. 1996, Sheikh et al. 
1999, Chiavegatto et al. 2000, Yamashita et al. 2005).  The content 
and distribution of gangliosides in developing rodent brain changes 
during maturation (Yu, Yen 1975, Seyfried, Miyazawa & Yu 1983, 
Seyfried 1987, Yu et al. 1988).   As both adult and neonatal Sandhoff 
mice treated with NSCs succumb to the disease, it might be important 
to target GM2 and GA2 storage in early stages of the disease to 
promote further longevity.  We injected neonatal SD mice with both 
NSCs and NB-DGJ to examine the effects of these therapies on GM2 
and GA2 content.  Although NSCs restored some level of β-
hexosaminidase enzyme activity by post-natal day 15, NB-DGJ had a 
more pronounced effect than NSCs on ganglioside storage at this early 
stage.  This effect was not, however, synergistically improved by the 
presence of NSCs.  These results indicate that substrate reduction is 
an important supplementation during early stages of preventative 
therapy involving NSCs. 
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MATERIALS AND METHODS 
Mice 
 The SV/129 Hexb-/- mice were obtained from Dr. Richard Proia (NIH).  
These mice were derived by the disruption of the murine Hexb gene 
and transferring this gene into the mouse genome via homologous 
recombination and embryonic stem cell technology as previously 
described (Sango et al. 1995).  Hexb-/- mice were derived from the 
crossing of Hexb+/- females with Hexb-/- males.  The genotypes of 
mice were determined enzymatically by a modification of the Galjaard 
procedure as described below (Galjaard 1979, Hauser et al. 2004, 
Kasperzyk et al. 2004).  Mice were propagated in the Boston College 
Animal Facility and were housed in plastic cages with filter tops 
containing Sani-Chip bedding (P.J. Murphy Forest Products Corp.; 
Montville, NJ).  Food and water were provided ad libitum.  Nursing 
females were provided with cotton nesting pads for the duration of the 
experiment.  All animal experiments were carried out with ethical 
committee approval in accordance with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals and were 
approved by the Institutional Animal Care Committee. 
 
NSC culture   
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We used a stable, clonal population of engraftable lacZ-expressing 
mNSCs (clone C17.2) with a history of successful mouse 
transplantation as well as fulfilling the operational definition of a stem 
cell, including enhanced expression of stemness genes that are 
constitutively self-regulated (facilitating expansion of homogenous 
monolayers) (Parker et al. 2005).  
 
Transplantation  
Guided by transillumination of the newborn mouse head, 2 µl of the 
NSC suspension (5 x 104 NSCs/µl in PBS) was gently expelled via a 
glass micropipette into each cerebral ventricle of anesthetized Hexb–/– 
pups (and unaffected littermate controls), allowing the NSCs access to 
the subventricular germinal zone.   
 
Histological and immunocytochemical assessment 
Fresh frozen ½ brains were fixed with 4% paraformaldehyde. For 
immunocytochemical analysis of 20-µm paraformaldehyde-fixed 
coronal cryosections, routine procedures were employed. E. coli β–
galactosidase (β-gal) in the mNSCs allowed reliable identification of 
donor-derived cells by β-gal-specific immunocytochemistry.  
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Confocal microscopy 
Images were acquired using a Bio-Rad MRC 1024 equipped with a 
single photon Kr/Ar laser and a Bio-Rad Radiance 2100MP equipped 
with a multiphoton laser and taken at 1024 × 1024 pixel resolution. 
Images were acquired sequentially to negate channel cross-talk. 
Negative and positive control images were taken with the same 
settings. Each merged image was visualized using orthogonal 
projections composed of 9–16 optical Z-planes 0.5- to 1-µm thick.  
 
NB-DGJ Treatment   
NB-DGJ was purchased from Toronto Research Chemicals, Inc. (North 
York, Ontario, Canada).  Neonatal Hexb-/- mice were injected with a 
Hamilton syringe (26 gauge, point style 2, 0.5 in needle length) daily 
(i.p.) from postnatal day 9 (p-9) to p-15 with either vehicle (0.9% 
saline) or NB-DGJ at 500 mg/kg body weight (Kasperzyk et al. 2004).   
 
β-hexosaminidase specific activity 
β-hexosaminidase activity was measured using 1 mM 4-
methylumbelliferyl-N-acetyl-β-D-glucosaminide (Sigma-Aldrich, St. 
Louis, MO) as the substrate (Galjaard 1979, Hauser et al. 2004, 
Kasperzyk et al. 2004).  Lyophilized tissues from ½ cortex were 
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homogenized in water and centrifuged for 5 minutes at 2000 x g.  The 
collected supernatants were added in duplicate to BD Falcon 96-well 
plates on ice.  Increasing volumes of 40µM 4-methylumbelliferone 
(Sigma-Aldrich, St. Louis, MO) in 0.9% NaCl were aliquoted as 
standards.  Plates were incubated at 37ºC for 30 minutes after the 
addition of substrate.  The reaction was stopped by the addition of 
0.5M Sodium Carbonate (pH 10.7). Fluorescent emission of 4-
methylumbelliferone was determined by a SpectraMax M5 micro-plate 
reader (Molecular Devices, Sunnyvale, CA) with excitation and 
emission set at 355 nm and 460 nm, respectively. Total protein 
concentrations for each tissue were determined by mixing an aliquot of 
each sample with Bio-Rad Protein Dye Reagent (Bio-Rad, Hercules, 
CA) diluted 1:4 (v/v) in water. Increasing concentrations of bovine 
serum albumin (BSA) (Sigma-Aldrich, St. Louis, MO) were used as 
standards. Plates were incubated at room temperature for 15 minutes, 
and read at 595 nm in the SpectraMax M5.  Specific β-hexosaminidase 
enzyme activity was expressed as nmol/mg protein/hr. 
 
Lipid isolation from cortex tissue 
Lipids were isolated from ½ cortex tissues of p-15 mice as described in 
chapter 2. 
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High Performance Thin Layer Chromatography 
Lipids were separated on HPTLC plates as described in chapter 2.  The 
equivalent of 1.5 µg of sialic acid was spotted for each ganglioside 
sample. The equivalent of 300 µg of brain dry weight was spotted for 
each asialo lipid sample.   
 
Quantification of ganglioside and asialo GM2 content 
The percentage distribution and density of the individual bands was 
determined by scanning the HPTLC plates on a Personal Densitometer 
SI with ImageQuant software (Molecular Dynamics, Sunnyvale, CA) for 
gangliosides or on a ScanMaker 4800 with ScanWizard5 V7.00 
software (Microtek, Carson, CA) for GA2. The total brain ganglioside 
distribution was normalized to 100%, and the percentage distribution 
values were used to calculate sialic acid concentration (micrograms of 
sialic acid per 100 mg dry weight) of individual gangliosides. The 
density values for GA2 were fit to a standard curve and used to 
calculate individual concentrations expressed as micrograms per 100 
mg dry weight. 
 
Statistics 
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All samples were compared by one way analysis of variance (ANOVA). 
 
RESULTS 
NSCs engraft and thrive in juvenile Sandhoff mouse brain 
Murine neural stem cells C17.2 have been well characterized for 
their ability to migrate to areas of neuropathology (Snyder et al. 1992, 
Snyder, Taylor & Wolfe 1995, Snyder et al. 1997, Yandava, Billinghurst 
& Snyder 1999, Aboody et al. 2000, Parker et al. 2005, Muller, Snyder 
& Loring 2006, Lee et al. 2007).  Following neonatal transplantation 
into the cerebral ventricles, we found that lacZ-expressing NSCs were 
widely dispersed in the Sandhoff mouse forebrain at post-natal day 15 
(Figure 14A-C). 
 
NSC implantation increases HexB enzyme activity in Sandhoff mouse 
brain 
Murine NSCs conferred a modest increase in enzymatic activity 
in adult Sandhoff mouse brain, which was sufficient to confer 
therapeutic benefit [(Lee et al. 2007)].  To determine if NSC 
engraftment influenced β-hexosaminidase enzyme activity in juvenile 
mice, we evaluated enzymatic activity in homogenized cortex tissues.  
Hex activity was slightly increased in SD mice that received NSCs 
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compared to untreated and saline-treated SD controls (Table 4). There 
was no difference in Hex enzymatic activity between SD mice that 
received NSC transplantation and mice that received NSCs + NB-DGJ 
treatments (Table 4). 
 
NB-DGJ partially corrects juvenile GM2 Ganglioside storage 
The influence of NSCs and NB-DGJ on total ganglioside sialic acid 
content is shown in Table 4. Total sialic acid content was similar in 
normal, SD, and NSC-treated mouse cortex at p-15.  Total sialic acid 
content was significantly reduced in mice treated with either NB-DGJ 
or NSCs + NB-DGJ compared to untreated SD mice. Total sialic acid 
content was similar in SD mice receiving either NB-DGJ alone or NSCs 
+ NB-DGJ dual therapy (Table 4). 
The gangliosides from each tissue were separated by HPTLC to 
determine their distribution and content (Figure 15 and Table 5).  
Gangliosides that represented less than 1% of total ganglioside 
content (such as GD3) were omitted from the total distribution.  GM2 
was undetectable in normal mouse cortex, whereas it comprised >5% 
of total ganglioside content in juvenile SD cortex (Figure 15 and Table 
5).  GM2 content was variable among the NSC-treated mice, but as a 
group there was no significant difference from untreated SD mice at p-
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15 (Table 5).  With the exception of GD1b, there was no significant 
difference between control and NSC-treated SD mice for other 
gangliosides. GM2, GD1a, GD1b, and GT1b content was significantly 
reduced in SD mice treated with either NB-DGJ or with the NB-
DGJ+NSC combined therapies (Figure 15 and Table 5).   The 
ganglioside distribution and GM2 content was similar for SD mice 
receiving NB-DGJ alone and SD mice receiving both treatments, 
indicating that there was no synergistic effect of the two therapies at 
p-15.  
 
NSCs and NB-DGJ reduce GA2 content in p-15 Sandhoff brain 
Despite having a nominal effect on GM2 content, NSC 
transplantation significantly reduced GA2 storage in juvenile SD mouse 
brain by 46% (Figure 16 and Table 4). We found that NB-DGJ 
treatment reduced GA2 content by >60% in SD mouse cortex, with no 
synergistic reduction seen when combined with NSC transplantation 
(Figure 16).   
 
DISCUSSION 
The success of combinational therapies for LSDs lies in the ability 
to suppress multiple underlying causes or symptoms of the disease.  
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For Sandhoff disease patients, the balance between active β-
hexosaminidase enzyme and the accumulation of glycosphingolipid will 
determine the onset, severity, and survivability of those affected.  
Here we demonstrate a combinational therapy approach that confers 
an immediate reduction in stored GM2 ganglioside, as well as an 
immediate (and potentially long-term) increase in β-hexosaminidase 
activity.  
NB-DGJ has been previously reported to reduce ganglioside 
biosynthesis along both the “a” and “b” pathways due to its 
competitive inhibition of GluCer synthase.   
Our findings mirrored the results seen in our previous studies in p-5 
Sandhoff mice, p-5 GM1 gangliosidosis mice, and p-15 GM1 
gangliosidosis mice (Kasperzyk et al. 2004, Kasperzyk et al. 2005, 
Baek et al. 2008).  Notably, GM1 content is not reduced in neonatal 
Sandhoff mice treated with NB-DGJ at the p-5 timepoint examined by 
Baek et al, or at the p-15 timepoint examined here.  Also, while it 
appears that substrate reduction significantly reduces GQ1b content at 
p-5 in both GM1 and GM2 gangliosidosis, it appears to have no effect 
on this complex ganglioside when measured at post-natal day 15 
(Kasperzyk et al. 2005). 
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 Previously, we reported that NB-DNJ or NB-DGJ administration 
at 600-1200 mg/kg/day in neonatal SD mice (p2-5) and juvenile GM1 
gangliosidosis mice (p-15) significantly increased murine sialidase 
activity, resulting in no net change or even an increase in asialo 
ganglioside content in drug treated mice (Baek et al. 2008, Kasperzyk 
et al. 2004, Kasperzyk et al. 2005).  However, decreases in asialo lipid 
content after substrate reduction therapy at higher doses has been 
reported in adult GM1 and GM2 gangliosidosis mouse models 
(Jeyakumar et al. 1999, Lee et al. 2007, Elliot-Smith et al. 2008).  At 
the concentration used in this study (500 mg/kg), the clear evidence 
of lessened GA2 burden may point toward age and dosage being 
important variables for therapeutic benefit. 
In this study we sought to see if the established therapeutic 
efficacy of stem cell implantation and NB-DGJ supplementation would 
confer an additive or synergistic reduction of the stored GM2 and GA2 
in Sandhoff mouse brain.  However, despite evidence that the stem 
cells were proliferating and producing detectable levels of enzyme at 
p-15, we found no significant correction of GM2 storage.  In Sandhoff 
mice, the primary action of NSCs is not neuronal replacement, but 
rather enzymatic cross correction (Lee et al. 2007, Jeyakumar et al. 
2009).  NSC implantation in an adult Sandhoff mouse model conferred 
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a 19% decrease in GM2 content 2 weeks after transplantation 
(Jeyakumar et al. 2009).  It is unknown whether differences in the 
developing mouse brain, such as active ganglioside biosynthesis, may 
have muted a comparable correction at juvenile stages of the disease.  
GM2 and GA2 storage were 3-fold and 2-fold greater, respectively, in 
30-day-old SD mouse brain than in the p-15 mouse brain examined 
here (Lee et al. 2007).  Enzymatic activity in NSC-treated SD mice was 
also 2 to 3-fold higher than in untreated SD mice at 30 days (Lee et al. 
2007).  As we did not see similar reconstitution of enzyme activity at 
p-15, this may explain the differences in ganglioside storage correction 
under similar conditions.  This also suggests that the effect of NSC-
driven cross correction improves over time. 
Both intra- and extracellular β-hexosaminidase isoenzyme 
activity from C17.2 stem cells is primarily HexB (two-thirds) and HexA 
(one-third) in vitro (Lee et al. 2007).  It is possible that, were this 
ratio maintained in vivo, that analysis of lipid content in juvenile brain 
would reflect a greater level of HexB, which primarily degrades GA2, 
rather than HexA, which is necessary to degrade GM2.  Further studies 
will be needed to establish if these minor enzymatic differences can 
explain the discrepancy in GM2 and GA2 correction.  
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The translation of stem cell therapies to the clinic is already 
underway (Guillaume et al. 2008, Selden et al. 2008, Lindvall, Kokaia 
2010, Schwarz, Schwarz 2010, Kohan et al. 2011).  As seen in the 
recent trial in neuronal ceroid lipofuscinoses (Batten’s disease), these 
therapies have been well tolerated in clinical patients (Lindvall, Kokaia 
2010, Kohan et al. 2011). With the data presented here, we have 
shown in the mouse model that neural stem cells may need to be 
supplemented by an early regimen of NB-DGJ in order to fully realize 
their therapeutic potential further down the line.   As the synergistic 
cooperation of these two therapies has already been established in an 
adult model, we propose that early and persistent substrate reduction 
therapy may yield the optimal results for patients seeking novel stem 
cell therapies. 
Recent findings indicate that the passage of imino sugars into 
the Sandhoff mouse brain can be synergistically improved by the 
calorie restricted ketogenic diet (Denny et al. 2010).  How caloric 
restriction or ketosis can directly impact the blood brain barrier is 
unknown.  In the near future, we plan to test the therapeutic 
properties of a new SRT drug specifically designed to bypass the multi-
drug resistance receptor (Mdr1a) at the blood brain barrier (Larsen et 
al. 2012).  Larsen et al. observed a significant decrease of 
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glucosylceramide content in brain of normal mice after 3 days of i.p. 
injection.  Should this novel drug prove more effective than the imino 
sugars in Sandhoff and GM1 gangliosidosis mice, it may point towards 
Mdr1a as a target for improving therapeutic efficacy of SRT drugs, 
despite previous reports to the contrary (Norris-Cervetto et al. 2006). 
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Figure 12. Lysosomal cross-correction delivers recombinant enzyme to 
deficient cells.  Glycosylated lysosomal enzymes (green circles) travel 
to the Golgi, where they acquire the mannose-6-phosphate group.  
The phosphorylated enzymes (red circles) then bind the mannose-6-
phosphate receptor, which targets them to lysosomes.  A small portion 
of enzyme (~10%) exits the cell, where it can bind to mannose-6-
phosphate receptors on adjacent cells.  ER, endoplasmic reticulum; 
Lys, Lysosome; M6PR, Mannose-6-Phosphate Receptor; ManR, 
Mannose Receptor (found only in fixed tissue macrophages).  Modified 
from Sands and Davidson (Sands, Davidson 2006). 
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Figure 13. Inhibition of ceramide glucosyltransferase by N-
butylgalactonojirimycin (NB-DGJ).  Adapted from Kasperzyk et al. 
(Kasperzyk et al. 2004b).  
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Figure 14. NSCs engraft throughout the forebrain following neonatal 
intraventricular transplantation.  β-gal-stained serial coronal sections 
through the brains of multiple representative 2 weeks old SD mice 
suggest substantial engraftments of NSCs in the cerebral cortex 
region.  a) 4',6-diamidino-2-phenylindole (DAPI) DNA stain (blue).  b) 
Donor-derived lacZ-expressing mNSCs were identified by FITC-tagged 
antibody to βgal (green). c) Merged image.  Scale bar = 25 µm. 
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nb
Control +/- 4 72.4 ± 2.3 526 ± 15
Control -/- 3 7.3 ± 0.3 535 ± 6 537 ± 21
NSC -/- 3 9.6 ± 0.7c 492 ± 28 294 ± 27d
NB-DGJ -/- 4 8.5 ± 0.2 414 ± 10d 172 ± 14d
NSC + NB-DGJ -/- 4 9.8 ± 0.6c 410 ± 16d 202 ± 22d
dIndicate that the value is significantly different from control (untreated Hexb-/-) mice at P < 0.01 
by One-Way ANOVA.
cIndicate that the value is significantly different from control (untreated Hexb-/-) mice at P < 0.05 
by One-Way ANOVA.
aValues represent mean ± standard error of the mean (SEM).
NSC, Neural Stem Cell; NB-DGJ, N-butylgalactonojirimycin; ND, not detectable.
bn, the number of independent mice analyzed.
ND
Treatment
Hexb 
Genotype
Table 4: Influence of NSC and NB-DGJ on !-hexosaminidase activity, total ganglioside content, and 
GA2 content in p-15 Sandhoff mouse braina
Total Sialic Acid 
(µg/100mg dry 
weight)
Hex Activity 
(nmol/mg 
protein/hr)
GA2 content 
(µg/100mg dry 
weight)
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Figure 15. HPTLC of cortex gangliosides in p-15 Sandhoff mice treated 
with mNSCs or NB-DGJ.  Gangliosides from untreated normal (HZ), 
untreated Sandhoff (SD), and SD mice treated with NSCs, 500 
mg/kg/day NB-DGJ from p-9 to p-15, or dual therapy were separated 
in a single 90 min ascending run in CHCl3 : CH3OH : dH20, 55 : 45 : 10 
(v:v:v) with 0.02% CaCl2.  The equivalent of 1.5 µg of sialic acid was 
spotted for each sample.  Ganglioside bands were visualized by 
spraying the plate with resorcinol-HCl and charring at 95ºC.  A 
summary of the densitometric analysis of the HPTLC plate is shown in 
Table 5. 
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Figure 16. Combinational therapy reduces stored GA2 in p-15 Sandhoff 
mouse cortex.  Asialo gangliosides were purified from the neutral lipid 
fraction of Sandhoff (SD) mice receiving no treatment, NSCs, 500 
mg/kg/day NB-DGJ, or dual therapy.  The plate was developed via a 
single 90 min ascending run in CHCl3 : CH3OH : dH20, (65 : 35 : 8; 
v/v/v) with 0.02% CaCl2-2H20.  The equivalent of 300 µg of brain dry 
weight was spotted for each sample.  GA2 bands were visualized by 
spraying the plate with orcinol-H2S04 and charring at 95ºC.  A GA2 
standard (4 µg shown) was used for quantification. Densitometric 
analysis of GA2 content is shown in Table 4.  GA2 was undetectable in 
HZ mouse cortex (data not shown). 
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CHAPTER FOUR 
Lasting Correction of Forebrain, Cerebellar, and Spinal Cord 
Neuropathy in Adult GM1 Gangliosidosis Mouse Brian by Adeno-
Associated Viral Gene Therapy 
 
INTRODUCTION 
Adeno-Associated Viral Gene Therapy 
As discussed in Chapter 3, cross-correctional therapy is an effective 
means to deliver normal or supernormal levels of enzyme to tissues 
that contain hypomorphic or knockout alleles of lysosomal hydrolases.  
Another method for delivering enzyme to βgal or Hex deficient cells is 
by incorporating the gene of interest into a viral vector delivery system 
and administering this vector to the host.  Adeno-associated viruses 
(AAVs) are different from adenoviruses in that they are single-
stranded rather than double-stranded DNA viruses (Sands, Davidson 
2006).  AAVs are non-enveloped viruses that are replication defective.  
The different AAV capsid serotypes (over 100 have been discovered) 
show affinity for different tissues.  This can be exploited when 
customizing the design of recombinant vectors. 
 The AAV genome is approximately 4.7kb, and contains two open 
reading frames, rep and cap (Kwon, Schaffer 2008) (Figure 17).  The 
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former encodes 4 viral replication proteins (Rep proteins), the latter 
encodes 3 structural proteins (VP1-3).  The ORFs are flanked by 5’ and 
3’ inverted terminal repeats (ITRs) (Kwon, Schaffer 2008).  These 
genes can be completely replaced, leaving ~3kb to insert a “gene of 
interest” and recombinant promoters (Figure 17).  Capsid 
pseudotyping involves inserting the genome of one AAV vector into the 
capsid of another (Kwon, Schaffer 2008).  Pseudotyping can be used 
to promote or alter the tissue affinity of distinct AAV vectors. 
 The cross-correction cycle of recombinant AAV vector is shown in 
Figure 18.  AAV2 binds to the heparan sulfate proteoglycan (HSPG) on 
the cell surface (Kwon, Schaffer 2008).  Viral gene expression 
potentially yields recombinant enzyme levels many fold greater than 
wild type cells for the purpose of cross-correction. 
 
AAV Therapy in Murine GM1 gangliosidosis  
AAV gene therapy has been shown to improve neuropathology in a 
variety of LSDs (Desmaris et al. 2004, Chen, Chang & Davidson 2009, 
Cachon-Gonzalez et al. 2006, Liu et al. 2005, Liu et al. 2007).  The 
intracerebroventricular (ICV) injection of AAV vector was well tolerated 
in neonatal GM1 gangliosidosis (βgal-/-) mouse, and this treatment 
dramatically elevated β-galactosidase enzymatic activity by 30 days of 
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age (Broekman et al. 2007).  Importantly, levels of GM1, GA1, 
cerebrosides, and sulfatides were normalized to wild-type levels in 
treated mice.  In a follow up study, AAV injections into the thalamus + 
deep cerebellar nuclei (DCN) of six to eight week-old βgal-/- mice 
corrected GM1 and GA1 storage in cortex, cerebellum, and brain stem 
at one month and four months post injection (Baek et al. 2010).  
Spinal cord was only partially corrected, however, and the injected 
βgal-/- mice eventually succumbed to the same progressive loss of 
motor coordination as the untreated mice. 
 From the previous studies, it became clear that the site(s) of 
injection play a vital role in the cross-corrective action of the vector 
(Broekman et al. 2009).  Secondly, CNS injections may not have been 
enough to rescue the mice from symptoms of peripheral storage once 
adulthood was reached.  Lastly, Broekman et al. showed that AAV 
serotype 8 capsids are up to 4x more efficient than AAV-1 or AAV-2 in 
transducing neurons in murine brain (Broekman et al. 2006).  In this 
study we examined the effect of intracerebroventricular (ICV) injection 
of AAV vector, expressing murine β-galactosidase, on adult βgal-/- 
mice.  A subset of the mice was given a subsequent injection in the tail 
vein, with a promoter specific to liver.  We found that AAV vector 
completely corrected GM1 and GA1 storage at 1 month and 8 months 
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after injection.  The lipid biochemistry corresponded to a sustained 
improvement in motor performance in both ICV-treated and dual-
treated (DT) groups.  These results point toward the cerebral 
ventricles as an ideal location for targeted gene therapy. 
 
MATERIALS AND METHODS 
 
AAV vector design and preparation  
The AAV vector used in this study, AAV2/8-chicken beta-actin 
promoter-gal, carries AAV2 inverted terminal repeats and the mouse 
lysosomal acid gal cDNA under transcriptional control of a hybrid CMV 
enhancer/chicken beta-actin promoter (CBA).  This AAV vector was 
derived from the plasmid pTR-UF12.1 (from Richard Snyder, University 
of Florida, FL) by removing the internal ribosome entry site-green 
fluorescent protein cassette and replacing it with a woodchuck 
hepatitis virus post-transcriptional regulatory element amplified from 
the plasmid CSCGW.  The AAV vector pseudotyped with an AAV8 
capsid (hence AAV2/8) was prepared with a titer of 6 x 1013g.c./ml as 
described previously (Broekman et al. 2007).  A second vector was 
made by removing the CBA promoter and replacing it with liver 
specific promoter, a hybrid Apolipoprotein E, enhancer/human alpha-I-
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anti-trypsin promoter (ApoE4/hAAT). This vector, AAV2/8-ApoE4/hAAT-
ßgal-W, was prepared with a titer of 1.25 x 1013g.c./ml.  Our 
collaborators Stan Leroy and Miguel Sena-Esteves at Harvard Medical 
School/Massachusetts General Hospital performed the vector design 
and injections. 
 
Mice  
The GM1-gangliosidosis mouse model was obtained from Dr. Kunihiko 
Suzuki (Neuroscience Center, University of North Carolina, Chapel Hill, 
NC).  Newborn mice for these experiments were generated by 
breeding ßgal+/- females to ßgal-/- males.  The genotype of mice was 
determined at post-natal day 25 by PCR.  The experimental protocol 
was approved by the Institutional Animal Care and Use Committee at 
the Massachusetts General Hospital and followed guidelines set forth in 
the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals.  
 
Animal Procedures  
Adult mice (6-8 weeks) deficient in ß-galactosidase (ßgal-/-) were 
separated into 2 groups, a single treatment group (n=14) and dual 
treatment group (n=17).  The dual treatment group was infused with 
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3 x 1011 gc of AAV2/8-ApoE4/hAAT-ßgal-W in 200ul of PBS via tail vein 
injection. Three days later this group received 2.4 x 1011 gc of AAV2/8-
CBA- ßgal-W into the lateral ventricles (AP -0.4, ML +1.0, DV -1.7 of 
the Bregma) infused at a rate of 4µl/minute for 1 minute.  The single 
treatment group received ventricular injections as described above.  
Injections were performed by our collaborators at MGH/HMS. 
 
Enzyme Assays  
β-galactosidase activity was measured using 1mM 4-
methylumbelliferyl-ß-D-galactopyranoside (Sigma-Aldrich, St. Louis, 
MO) as the substrate.  Lyophilized tissues from cerebrum, cerebellum, 
and spinal cord were homogenized in water and centrifuged for 5 
minutes at 3000 rpm.  The collected supernatants were added in 
duplicate to BD Falcon 96-well plates on ice.  Increasing volumes of 
40µM 4-methylumbelliferone (Sigma-Aldrich, St. Louis, MO) in 0.9% 
NaCl were plated as standards.  Plates were incubated at 37ºC for 30 
minutes after the addition of substrate.  The reaction was stopped by 
the addition of 0.5M Sodium Carbonate, pH 10.7. Fluorescent emission 
of 4-methylumbelliferone was determined by a SpectraMax M5 micro-
plate reader (Molecular Devices, Sunnyvale, CA) with excitation and 
emission set at 355nm and 460nm, respectively. Total protein 
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concentrations for each tissue were determined by mixing an aliquot of 
each sample with Bio-Rad Protein Dye Reagent (Bio-Rad, Hercules, 
CA) diluted 1:4 in water. Increasing concentrations of bovine serum 
albumin (BSA) (Sigma-Aldrich, St. Louis, MO) were plated as 
standards. Plates were incubated at room temperature for 15 minutes, 
and read at 595nm in the SpectraMax M5.  Specific ß-galactosidase 
enzyme activity is expressed as nmol/mg protein/hr. 
 
Tissue Preparation  
Animals were sacrificed using carbon dioxide asphyxiation.  The tissues 
were either flash frozen in vapor phase of liquid nitrogen or post-fixed 
in 4% paraformaldehyde (PFA) (Electron Microscopy Sciences, 
Hatfield, PA) then cryoprotected in 30% sucrose based on the 
downstream histology and biochemical protocols.  The brain, 
cerebellum, brainstem, and spinal cord were harvested as well as liver, 
spleen, heart and lung.  Tissue collections were performed by our 
collaborators at MGH/HMS. 
 
High Performance Thin Layer Chromatography 
All lipids were analyzed qualitatively by high-performance thin-layer 
chromatography (HPTLC) according to previously described methods. 
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Lipids were spotted on 10 x 20 cm Silica gel 60 HPTLC plates (E. 
Merck, Darmstadt, Germany) using a Camag Linomat III auto-TLC 
spotter (Camag Scientific, Inc., Wilmington, NC). The amount of lipid 
per lane was equivalent to 1.5 µg of total sialic acid for gangliosides 
and 0.2 mg of tissue dry weight for GA1. For gangliosides and GA1, the 
HPTLC plates were developed by a single ascending run with 
CHCl3/CH3OH/dH2O (55:45:10, v/v for gangliosides; 65:35:8, v/v for 
GA1) containing 0.02% CaCl2-2H2O. The plates were sprayed with 
either the resorcinol-HCl reagent or the orcinol-H2SO4 reagent and 
heated at 95ºC for 10 minutes to visualize gangliosides or GA1, 
respectively. The percentage distribution and density of the individual 
bands was determined by scanning the plates on a Personal 
Densitometer SI with ImageQuant software (Molecular Dynamics, 
Sunnyvale, CA) for gangliosides or on a ScanMaker 4800 with 
ScanWizard5 V7.00 software (Microtek, Carson, CA) for GA1. The total 
brain ganglioside distribution was normalized to 100%, and the 
percentage distribution values were used to calculate sialic acid 
concentration (micrograms of sialic acid per 100 mg dry weight) of 
individual gangliosides. The density values for GA1 were fit to a 
standard curve and used to calculate individual concentrations 
expressed as micrograms per 100 mg dry weight. 
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Statistics 
All samples were compared by one way analysis of variance (ANOVA).  
Samples from AAV-treated mice were pooled for analysis, as there 
were no differences in the CNS ganglioside profile or CNS enzyme 
activity between mice that received an ICV injection compared to mice 
that received both ICV and tail vein injections. 
 
RESULTS 
β-galactosidase specific activity is increased brain and spinal cord of 
AAV-treated GM1 gangliosidosis mice 
Tissue homogenates from normal, GM1, and AAV-treated GM1 
mice were assayed for β-gal specific enzymatic activity using the 
fluorescent substrate 4-methylumbelliferyl-β-D-galactopyranoside.  In 
cortex and cerebellum, β-gal activity (nmol/mg protein/hr) was 10-fold 
and 100-fold greater in the AAV-treated βgal-/- mice than in the 
untreated βgal+/- or untreated βgal-/- mice, respectively (Figure 19).  
In spinal cord, β-gal activity was 3-fold and 30-fold greater in the AAV-
treated βgal-/- mice than in the untreated βgal+/- or untreated βgal-/- 
mice, respectively (Figure 19).  These ratios were consistent at 1 
month and 8 months post-treatment (3 months and 10 months of age, 
respectively). 
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GM1 and GA1 content were completely corrected in AAV-treated GM1 
mice 
 The total sialic acid content (µg/100 mg dw) of AAV-treated βgal-
/- mice was significantly less than in untreated βgal-/- mice, and 
similar to untreated βgal+/- mice (Tables 6-8).  The distribution of 
gangliosides was quantified by high performance thin-layer 
chromatography (Figures 20-22, Tables 6-8).  GM1 content was 
returned to wild-type levels in AAV-treated βgal-/- mice at 1 month 
after treatment (Figures 20-22, Tables 6-8), and this correction was 
sustained at 8 months after treatment (Figures 20-22, Tables 6-8).  
GA1 was present at only trace amounts at 1 month post-treatment in 
cerebellum and spinal cord of AAV-treated βgal-/- mice, and 
completely undetectable at 8-months post-treatment (Table 9).   
 
DISCUSSION 
 Here we have shown that a single injection of AAV vector coding 
for β-galactosidase into the cerebral ventricles is sufficient to 
completely clear glycolipid storage in an adult murine model of GM1 
gangliosidosis.  These data further establish that AAV therapy works 
not only swiftly, but continues to produce therapeutic enzyme for the 
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life of the animals.  This is important, as re-administration in patients 
is likely to provoke an immune response.  Unlike our previous study, 
which involved injections in the thalamus and deep cerebellar nuclei 
(DCN), ICV injection completely corrected lipid storage in the spinal 
cord (Baek et al. 2010).  Amazingly, this corresponded with a 
sustained improvement in motor performance, another benefit not 
seen with the thalamus/DCN injections (Baek et al. 2010).  These 
findings suggest that ICV injection may be ideal for correction across 
the CNS, and that supplementary peripheral injections may improve 
long-term peripheral pathology.
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Figure 17. The recombinant AAV shuttle vector.  The 4.7kb AAV 
genome contains two open reading frames, encoding 4 viral replication 
(Rep) proteins and 3 structural (Cap) proteins.  The ORFs are flanked 
by 5’ and 3’ inverted terminal repeats (ITRs) necessary for efficient 
multiplication of the viral genome.  Modified from Romano (Romano 
2005). 
 
  
  95 
  
  96 
Figure 18. AAV infection, enzyme production, and cross-correction.  
The gene of interested inserted into the AAV genome is transcribed in 
the host nucleus, and then translated into functional protein in the ER 
and post-translationally modified in the Golgi.  From there, it can 
either be packaged into lysosomes or released into the extracellular 
space. From http://commonhealth.wbur.org/2011/11/tay-sachs-
human-trial/ courtesy of Dr. Miguel Sena-Esteves. 
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Figure 19. β-galactosidase enzymatic activity in untreated βgal+/- 
(HZ), untreated βgal-/- (KO), and AAV-βgal injected βgal-/- (AAV) 
mouse CNS. βgal-/- (KO) mice were injected with AAV-βgal at 2 
months and assayed for activity in A) cerebrum, B) cerebellum, and C) 
spinal cord at one month and eight months after injection, 
corresponding to 3 months and 10 months of age, respectively.  βgal 
enzyme activity is expressed as nmol/hour/mg protein.  Values are 
expressed as mean ± SEM, or mean ± IQR when n = 2.  The number of 
independent mice analyzed was 2-6 per group. 
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Figure 20. HPTLC of cortical gangliosides in untreated βgal+/- (HZ), 
untreated βgal-/- (KO), intracerebroventricular (ICV) AAV-βgal infused 
βgal-/-, and ICV + tail vein AAV-βgal dual treated (DT) βgal-/- mice.  
The amount of ganglioside sialic acid spotted per lane was equivalent 
to 1.5 µg sialic acid.  The plate was developed in a single ascending 
run (90 min) with chloroform: methanol: water (55:45:10 v/v/v) 
containing 0.02% calcium chloride.  The bands were visualized by 
spraying with the resorcinol reagent and heating to 95°C. 
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Figure 21. HPTLC of cerebellar gangliosides in untreated βgal+/- (HZ), 
untreated βgal-/- (KO), intracerebroventricular (ICV) AAV-βgal infused 
βgal-/-, and ICV + tail vein AAV-βgal dual treated (DT) βgal-/- mice.  
The amount of ganglioside sialic acid spotted per lane was equivalent 
to 1.5 µg sialic acid.  The plate was developed in a single ascending 
run (90 min) with chloroform: methanol: water (55:45:10 v/v/v) 
containing 0.02% calcium chloride.  The bands were visualized by 
spraying with the resorcinol reagent and heating to 95°C. 
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Figure 22.  HPTLC of spinal cord gangliosides in untreated βgal+/- 
(HZ), untreated βgal-/- (KO), intracerebroventricular (ICV) AAV-βgal 
infused βgal-/-, and ICV + tail vein AAV-βgal dual treated (DT) βgal-/- 
mice.  The amount of ganglioside sialic acid spotted per lane was 
equivalent to 1.5 µg sialic acid.  The plate was developed in a single 
ascending run (90 min) with chloroform: methanol: water (55:45:10 
v/v/v) containing 0.02% calcium chloride.  The bands were visualized 
by spraying with the resorcinol reagent and heating to 95°C. 
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ßgal+/- 3 -
ßgal-/- 3 -
ßgal-/- 3 AAVb
ßgal+/- 10 -
ßgal-/- 10 -
ßgal-/- 10 AAV
Table 9. Effect of AAV vector on GA1 concentration of ßgal-/- mice*
Age 
(months) TreatmentStrain
CerebellumCerebrum
ND NDND
ND, not detected
* Values are expressed as the mean ± SEM except when the number of 
independent samples is 2, where values are expressed as mean ± 
interquartile range. N = 2-6 mice per group.
Trace
ND
1.7 ± 0.1
5.7 ± 0.97.0 ± 6.2
Spinal Cord
GA1a
ND
(mg/100 mg dry weight)
ND
5.6 ± 0.3
11.6 ± 1.5
3.0 ± 0.4
ND
ND
a Asialo ganglioside were determined by densitometric scanning of HPTLC 
plates.
b AAV, pooled data for mice treated by either ICV injection or ICV/IV dual 
injection of AAV2/8-CBA-ßgal.
ND
Trace
ND
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CHAPTER FIVE 
Administration of Both β-Hexosaminidase Subunits is Necessary and 
Sufficient to Completely Correct GM2 Storage in a Murine Model of 
Late Onset Tay-Sachs Disease 
 
INTRODUCTION 
Tay-Sachs (Hexa-/- knockout) mice are generally asymptomatic during 
the pathological lifespan of Sandhoff (Hexb-/-) mice, owing to the 
activity of murine sialidase (Sango et al. 1995).  Hex A protein (alpha-
beta heterodimer) and the GM2 activator are required for the catabolic 
removal of GalNac from GM2 ganglioside in the lysosome.  However, 
since Tay-Sachs mice still have functional Hex B protein (beta-beta 
homodimer), they can readily catabolize asialo GM2 (GA2), delaying or 
preventing the pathology associated with murine Sandhoff disease 
(Yamanaka et al. 1994, Phaneuf et al. 1996).  The neuropathology of 
Late Onset Tay-Sachs (LOTS) disease can be induced in female Hexa-
/- mice by repeat breeding (Jeyakumar et al. 2002).  In addition, 
Hexa-/- mice more than 11-12 months old may exhibit slow and 
progressive neurodegeneration, making them an appropriate model for 
studying LOTS in vivo (Miklyaeva et al. 2004). 
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 Previous research has shown that Adeno-associated viral (AAV) 
delivery of recombinant Hex beta subunit is sufficient to correct GM2 
storage and associated neuropathology in SD mice (Cachon-Gonzalez 
et al. 2006).  However, delivery of recombinant Hex alpha subunit via 
retroviral vector either failed to rescue Hexa-/- fibroblasts that were 
not directly transduced, or reduced levels of Hex B enzyme as a side 
effect of alpha overexpression (Guidotti et al. 1998, Martino et al. 
2002).  In murine models of Tay-Sachs disease, co-administration of 
both alpha and beta subunits has been demonstrated as necessary to 
completely correct peripheral tissue pathology (Guidotti et al. 1999), 
though there have been reports that Hex alpha alone can correct 
storage in the CNS (Martino et al. 2005).    
Here, we sought to test whether AAV vector delivery of Hex 
alpha, Hex beta, or co-administration of both vectors were able to 
correct GM2 storage in murine LOTS brain.  We performed bilateral 
injections of recombinant AAV2/1 into 8 month old LOTS striatum, and 
assessed cortical Hex A isoenzyme activity, sialic acid content, 
ganglioside distribution, neutral lipid content, and acidic lipid content 
at 2 months post-injection.  We found that delivery of the alpha 
subunit alone increased Hex A enzymatic activity, but failed to 
significantly reduce GM2 content in all animals tested.  Administration 
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of the beta subunit alone had no effect on ganglioside content.  
Delivery of both alpha and beta subunits together further increased 
Hex A activity and almost completely corrected GM2 storage.  These 
data offer important considerations for differences in clinical therapies 
in the GM2 gangliosidoses. 
 
MATERIALS AND METHODS 
Mice 
Mice were housed at the University of Cambridge Department of 
Medicine in the lab of our collaborator Dr. Begona Cachon-Gonzalez.  
Hexa-/- mice were generated, identified, and housed according to their 
previously described methods (Cachon-Gonzalez et al. 2006).   
 
AAV vector design 
The AAV vector used in this study was constructed as previously 
described by our collaborators in the lab of Dr. Cachon-Gonzalez 
(Cachon-Gonzalez et al. 2006). The AAV2 genome contains the murine 
Hexα or Hexβ cDNA under the control of Chicken β-actin (CBA) 
promoter and the woodchuck hepatitis post-transcriptional regulatory 
element (WPRE), packaged in the AAV1 capsid.    
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Surgery 
Stereotaxic coordinates (in mm) for the striatum relative to bregma 
were A -0.1, L ± 2.0, V -3.0 for the two injection sites.  Hyperosmotic 
concentrations of mannitol were added to the injections, as it has been 
shown to enhance vector delivery in murine brain (Bourgoin et al. 
2003).  8 month old Hexa-/- mice received bilateral striatal injections 
with 1.1µl AAV2/1 α1 (9.9x109 g.c.) + 1.1µl PBS + 0.8µl 20% 
mannitol (Hex alpha group), 1.1µl AAV2/1 β1 (9.9x109 g.c.) + 1.1µl 
PBS + 0.8µl 20% mannitol (Hex beta group), or 1.1µl AAV2/1 α1 
(9.9x109 g.c.) + 0.8µl AAV2/1 β1 (9.9x109 g.c.) + 0.3µl PBS + 0.8µl 
20% mannitol (Hex alpha + beta group).  Mice were sacrificed one 
month after injection. 
 
Tissue Preparation 
Tissue was prepared as previously described and shipped to Boston 
College on dry ice for analysis (Cachon-Gonzalez et al. 2006). 
 
Enzyme Assays  
β-hexosaminidase (Hex) A activity was measured using 1mM 4-
Methylumbelliferyl-7-(6-sulfo-2-acetamido- 2-deoxy-β-D-
glucopyranoside) (Sigma-Aldrich, St. Louis, MO) as the substrate.  
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Lyophilized tissues from mouse cerebrum were homogenized in water 
and centrifuged for 5 minutes at 3000 rpm.  The collected 
supernatants were added in duplicate to BD Falcon 96-well plates on 
ice.  Increasing volumes of 40µM 4-methylumbelliferone (Sigma-
Aldrich, St. Louis, MO) in 0.9% NaCl were plated as standards.  Plates 
were incubated at 37ºC for 30 minutes after the addition of substrate.  
The reaction was stopped by the addition of 0.5M Sodium Carbonate, 
pH 10.7. Fluorescent emission of 4-methylumbelliferone was 
determined by a SpectraMax M5 micro-plate reader (Molecular 
Devices, Sunnyvale, CA) with excitation and emission set at 355nm 
and 460nm, respectively. Total protein concentration for each tissue 
was determined by mixing an aliquot of each sample with Bio-Rad 
Protein Dye Reagent (Bio-Rad, Hercules, CA) diluted 1:4 in water. 
Increasing concentrations of bovine serum albumin (BSA) (Sigma-
Aldrich, St. Louis, MO) were plated as standards. Plates were 
incubated at room temperature for 15 minutes, and read at 595nm in 
the SpectraMax M5.  Specific β-hexosaminidase A enzyme activity is 
expressed as nmol/mg protein/hr. 
 
Total lipid isolation 
Total lipids were isolated and purified from cerebral cortex as 
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previously described (Hauser et al. 2004, Kasperzyk et al. 2004). 
Frozen cortex samples were homogenized in water and lyophilized for 
24 h. After desiccation, the dried tissue was weighed and resuspended 
in water, and lipids were extracted overnight in CHCl3-CH3OH 1:1. 
Lipids were further separated into a neutral (F1) and acidic/ganglioside 
(F2) fraction via ion exchange chromatography over a Sephadex 
column. Neutral lipids (phosphatidylcholine, 
phosphatidylethanolamine, plasmalogens, ceramide, sphingomyelin, 
cerebrosides, and GA2) and cholesterol were eluted with CHCl3-
CH3OH-dH2O (30:60:8; v/v/v). Acidic phospholipids 
(phosphatidylinositol, phosphatidylserine, phosphatidic acid, 
cardiolipin, sulfatides, and fatty acids) and gangliosides were eluted 
with CHCl3-CH3OH-0.8 M C2H3NaO2 (30: 60: 8; v/v/v). 
 
Sialic acid quantification   
Gangliosides were further separated from acidic phospholipids and 
desalted as previously described (Hauser et al. 2004, Kasperzyk et al. 
2004). Total ganglioside content was quantified before and after 
desalting using the resorcinol assay. Three aliquots of each ganglioside 
sample were dried under vacuum. A resorcinol-dH2O, 1:1, v/v solution 
(resorcinol reagent-HCl-0.2 M resorcinol- dH2O-0.1 M CuSO4, 40: 5: 
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5: 0.125, v/v/v/v) was added to each sample, followed by submersion 
in a boiling water bath for 17 min. After cooling on ice, the reaction 
was stopped with butyl acetate-N-butanol, 85:15, v/v. Each sample 
was vortexed and centrifuged at 700 g for 2 min. The absorbance of 
the upper aqueous layer was recorded at 580 nm using a Shimadzu 
UV-1601 spectrophotometer (Shimadzu; Torrance, CA). Sialic acid 
values were fit to a standard curve using N-acetylneuraminic acid as a 
standard. 
 
High-performance Thin Layer Chromatography 
Lipids were spotted on 10 × 20 cm silica gel-60 high-performance TLC 
(HPTLC) plates using a Camag Linomat III auto-TLC spotter (Camag 
Scientific, Inc.; Wilmington, NC) as previously described (Hauser et al. 
2004, Kasperzyk et al. 2004, Macala, Yu & Ando 1983).  The amount 
of lipid per lane was equivalent to 1.5 µg sialic acid for gangliosides, 
70 µg dry weight for neutral lipids, 200 µg dry weight for acidic lipids, 
and 300 µg dry weight for GA2.  Gangliosides were separated by a 
single ascending run (90 min) in a solution of CHCl3-CH3OH-0.02% 
CaCl2 (55:45:10; v/v/v). Asialo gangliosides were separated by a 
single ascending run (90 min) in a solution of CHCl3-CH3OH-0.02% 
CaCl2 (55:45:10; v/v/v). Neutral or acidic lipids were separated by an 
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initial ascending run (up to 4.5 cm or 6.0 cm, respectively) with a 
solution of CHCl3-CH3OH-acetic acid-formic acid-dH2O (35:15:6:2:1; 
v/v/v/v/v), dried for 15 min, and then run to the top with hexane-
diisopropyl ether-acetic acid (65:35:2; v/v/v) (Fisher Scientific). 
Gangliosides were visualized by spraying the dried plates with the 
resorcinol reagent, followed by heating at 95°C. Neutral and acidic 
lipids were visualized by dipping the dried plates into 3% cupric 
acetate in an 8% phosphoric acid solution, followed by heating the 
plate to 140°C.  Asialo lipids were visualized by spraying the dried 
plates with the orcinol reagent, followed by heating at 95°C. (Macala 
et al, 1983). 
 
Ganglioside and lipid quantification 
A Personal Densitometer SI with ImageQuant software (Molecular 
Dynamics; Sunnyvale, CA) was used to estimate the concentrations of 
lipids on HPTLC. The total ganglioside content was normalized to 
100%, and the percent distribution of each band was used to 
determine the sialic acid concentration for individual gangliosides.  
Ganglioside content was expressed as µg sialic acid/100 mg dry 
weight.  For neutral and acidic plates, the band density values for 
cerebrosides and sulfatides, respectively, were fit to a standard curve 
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and used to determine the concentration of each lipid, expressed as 
µg/mg dry weight.  For asialo plates, the band density values for GA2 
were fit to a standard curve and expressed as µg/mg dry weight. 
 
Statistics 
All experimental groups were compared using the One Way Analysis of 
Variance (ANOVA). 
 
RESULTS 
AAV vector treatment increases Hex A enzyme activity 
Hex A specific enzymatic activity (nmol/mg protein/hr) was reduced 3-
fold in Hexa-/- mice cortex compared to Hexa+/- controls (Figure 23).  
Striatal injection of Hex alpha subunit (AAV-Hexα) had no effect on 
Hex A activity in two of the three injected mice, while substantially 
increasing Hex A activity in the third.  Thus, Hex A activity was 3-fold 
greater in Hexa-/- mice injected with AAV-Hexα compared to 
untreated Hexa-/- mice, but this difference was not significant (Figure 
23).  Hex A activity was 15-fold and 40-fold higher in Hexa-/- mice 
receiving both Hex alpha + Hex beta subunits (AAV-Hexα+β) 
compared to untreated Hexa+/- and Hexa-/- control mice, respectively 
(Figure 23). 
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Dual vector administration corrects ganglioside storage in LOTS mouse 
brain 
Total sialic acid content in cortex of untreated HexA-/- mice was 
greater than Hexa+/- mice, due to the accumulation of GM2 
ganglioside (Figure 24, Table 10).  Total sialic acid and GM2 content 
were unchanged in Hexa-/- mice following injection with either AAV-
Hexα or AAV-Hexβ alone (Figure 24, Table 10).  Dual administration of 
AAV-Hexα+β restored total sialic acid content to normal levels and 
reduced GM2 storage >90% in Hexa-/- cortex (Figure 24, Table 10).  
Interestingly, GM3 was detected in mice receiving any of the AAV-Hex 
injections (Figure 24, Table 10).  GM1, GD1a, GT1a, GD1b, GT1b, and 
GQ1b content were similar in Hexa+/-, untreated Hexa-/-, and AAV-
Hex treated Hexa-/- cortex (Table 10). 
 
Hex beta is necessary to clear GA2 storage 
Unlike late-stage Sandhoff and GM1 gangliosidosis mice, adult 
LOTS mice do not have any significant changes in their neutral or 
acidic lipid profiles compared to normal mice, which is consistent with 
their milder neuropathy (Figure 25, Figure 26).  Myelin enriched 
glycolipids cerebrosides and sulfatides were similar in Hexa+/-, 
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untreated Hexa-/-, and AAV-Hex treated Hexa-/- cortex (Table 11).  
GA2 storage was detectable in Hexa-/- brain, though at a 
concentration roughly 40-fold less than that found in adult Sandhoff 
brain (Table 11) (Denny et al, 2010).  There was no change in GA2 
content after administration of AAV-Hexα (Table 11).  GA2 was 
undetectable in Hexa-/- mice injected with either AAV-Hexβ or AAV-
Hexα+β (Table 11).  Thus, recombinant Hex B enzyme is necessary to 
clear murine LOTS cortex of this secondary storage material. 
 
DISCUSSION 
We have previously demonstrated that AAV-mediated gene 
therapy is a viable strategy for delivery of corrective enzyme in 
neonatal and young adult mouse models of GM1 gangliosidosis 
(Broekman et al. 2007, Baek et al. 2010, Chapter 3).  For the GM2 
gangliosidoses, it has been suggested that the production of β-
hexosaminidase heterodimers (Hex A) is rate-limited by the wild-type 
production of the non-injected subunit (Guidotti et al. 1999).  Here we 
show near complete correction of GM2 and GA2 storage in a murine 
model of late onset Tay-Sachs disease after striatal injection of AAV 
vector.  Notably, Hexa-/- mice injected with AAV-Hexα did not produce 
sufficient Hex A enzyme to correct GM2 storage.  As the AAV-Hexα and 
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AAV-Hexα+β groups received the same viral load of Hexα, we can 
conclude that the co-administration of Hexβ resulted in the formation 
of more functional Hex A heterodimers.  Only this dramatic increase in 
Hex A enzyme was sufficient for cross-correction in mouse cortex. 
 In addition to increasing Hex A enzymatic activity, the co-
administration of AAV-Hexβ corrected the storage of GA2 in Hexa-/- 
mouse cortex.  The pathogenesis associated with GA2 storage has not 
been well established, and Hexa-/- mice exhibited far less storage of 
asialo glycosphingolipid than GM1 gangliosidosis or Sandhoff disease 
mice.  The clearing of secondary storage material, however minor, is 
still clinically relevant as human TS patients may lack sufficient 
sialidase activity to clear GM2 storage through this pathway. 
 The observation that all AAVHex treated samples exhibited an 
increase in GM3 (which was not seen in control Hexa+/- or Hexa-/- 
brain) offers some insight into the dynamics of clearance in gene 
therapy models.  In the glycosphingolipid catabolism pathway, the first 
breakdown products of GM2 and GA2 will be GM3 and LacCer, 
respectively (Sango et al. 1995).  In a cellular environment where the 
level of GM2/GA2 clearance has not yet outpaced the level of 
production/storage, an increase in these catabolites may be expected.  
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In future experiments, it may be interesting to see what effect, if any, 
this therapy has on LacCer levels in cortex. 
 For the first time, we have demonstrated the utility of AAV 
vector gene therapy in 8-month old murine brain.  As these mice have 
reached neuronal and physical maturation, the toleration of vector and 
the relatively short turn-around for correction (2 months) offers 
promising insights for clinical applications of this therapy in patients 
with late onset, progressive neurodegeneration.  These data also 
suggest that the dramatic improvements seen in GM2 gangliosidosis 
models treated with viral vector gene therapy can be improved by co-
administration of both β-Hexosaminidase subunits. 
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Figure 23. AAV vector administration dramatically increases Hex A 
enzymatic activity in LOTS mouse cortex.  Hex A activity is expressed 
as nmol/hour/mg protein and the values are expressed as mean ± 
SEM.  The number of independent mice analyzed was 3 per group. 
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Figure 24. Ganglioside distribution in cortex of 10-month old normal 
(HZ) and LOTS (KO) mice treated with AAV-Hex at 8-months of age.  
The amount of ganglioside sialic acid spotted per lane was equivalent 
to 1.5 µg sialic acid.  The plate was developed in a single ascending 
run (90 min) with chloroform: methanol: water (55:45:10 v/v/v) 
containing 0.02% calcium chloride.  The bands were visualized by 
spraying with the resorcinol reagent and heating to 95°C.  
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Strain Treatment nc
HexA +/- - 301 ± 25 3 456.0 ± 29.1 ND ND 51.3 ± 0.2 170.7 ± 6.4 15.1 ± 0.9 35.7 ± 4.0 148.8 ± 15.4 34.3 ± 3.5
HexA -/- - 260 ± 8 3 583.0 ± 27.2 ND 134.6 ± 11.7g 50.9 ± 3.1 172.8 ± 8.4 16.5 ± 0.4 34.8 ± 1.9 145.0 ± 3.2 28.4 ± 1.7
HexA -/- AAV-Hex alphad 309 ± 7 3 539.3 ± 44.7 2.9 ± 2.9 121.2 ± 47.0g 44.9 ± 1.2 161.9 ± 4.1 18.4 ± 0.5 34.5 ± 1.6 128.3 ± 2.3 27.1 ± 1.4
HexA -/- AAV-Hex betae 337 ± 1 3 589.7 ± 14.9g 6.8 ± 3.6 152.9 ± 12.1g 54.4 ± 2.2 166.3 ± 4.0 19.9 ± 1.1g 29.9 ± 1.0 124.9 ± 5.7 34.5 ± 3.6
HexA -/- AAV-Hex !+"f 304 ± 9 3 429.7 ± 0.1h 6.5 ± 0.8 13.1 ± 1.6h 51.9 ± 2.0 151.7 ± 4.0 16.1 ± 0.6 34.9 ± 1.0 127.5 ± 0.2 28.3 ± 2.6
Table 10: Effect of AAV vector on Cortical Ganglioside distribution in adult LOTS mousea
aValues are expressed as the mean ± standard error of the mean (SEM).
GM2 GM1 GD1a
hSignificantly different from the untreated HexA -/- group at P < 0.05 by One Way ANOVA.
Age (days)
gSignificantly different from the untreated HexA +/- group at P < 0.05 by One Way ANOVA.
GM3Total Sialic Acid
Concentration (ug/100mg dry weight)b
ND, not detectable.
cn, the number of independent samples per group.
dMice received bilateral striatal injections with 1.1µl AAV2/1 !1 (9.9x109 g.c.) + 1.1µl PBS + 0.8µl 20% mannitol.  
eMice received bilateral striatal injections with 1.1µl AAV2/1 "1 (9.9x109 g.c.) + 1.1µl PBS + 0.8µl 20% mannitol.  
fMice received bilateral striatal injections with 1.1µl AAV2/1 !1 (9.9x109 g.c.) + 0.8µl AAV2/1 "1 (9.9x109 g.c.) + 0.3µl PBS + 0.8µl 20% mannitol.  
GT1a
bTotal sialic acid content was determined by the resorcinol assay.  Concentrations of gangliosides were determined by densitometric scanning of HPTLC plates.
GD1b GT1b GQ1b
  128 
Figure 25. Neutral lipid content in cortex of 10-month old normal (HZ) 
and LOTS (KO) mice treated with AAV-Hex at 8-months of age.  The 
amount of neutral lipid spotted per lane was equivalent to 70 µg tissue 
dry weight.  The plate was developed to a height of 4.5 cm with 
chloroform: methanol: acetic acid: formic acid: water (35:15:6:2:1; 
v/v/v/v/v), then run to the top with hexane: diisopropyl ether: acetic 
acid (65:35:2; v/v/v). The bands were visualized by charring with 3% 
cupric acetate in 8% phosphoric acid solution.  CE – Cholesterol 
Esters; TG – Triglycerides; IS – Internal Standard (Oleyl Alcohol); Chol 
– Cholesterol; Cer – Ceramide; CB – Cerebrosides (doublet); PE – 
phosphatidylethanolamine; PC – Phosphatidylcholine; SM – 
Sphingomyelin. 
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Figure 26. Acidic lipid content in cortex of 10-month old normal (HZ) 
and LOTS (KO) mice treated with AAV-Hex at 8-months of age.  The 
amount of acidic lipid spotted per lane was equivalent to 200 µg tissue 
dry weight.  The plate was developed to a height of 6.0 cm with 
chloroform: methanol: acetic acid: formic acid: water (35:15:6:2:1; 
v/v/v/v/v), then run to the top with hexane: diisopropyl ether: acetic 
acid (65:35:2; v/v/v). The bands were visualized by charring with 3% 
cupric acetate in 8% phosphoric acid solution.  Excess ganglioside in 
LOTS acidic fraction migrated near the origin.  FA – Fatty Acids; CL – 
Cardiolipin; PA – Phosphatidic Acid; Sulf – Sulfatides (doublet); PS- 
Phosphatidylserine; PI – Phosphatidylinositol. 
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Strain Treatment nc
HexA +/- - 3 ND 43.9 ± 4.6 13.7 ± 0.4
HexA -/- - 3 1.1 ± 0.2d 41.8 ± 2.4 14.0 ± 1.2
HexA -/- AAV-Hex alpha 3 0.8 ± 0.1d 45.3 ± 5.9 13.7 ± 0.5
HexA -/- AAV-Hex beta 3 NDe 46.0 ± 6.3 14.2 ± 1.4
HexA -/- AAV-Hex !+" 3 NDe 51.1 ± 5.7 14.0 ± 2.2
Concentration (ug/mg dry weight)b
Table 11: Effect of AAV vector on Cortical GA2 and phospholipid content in adult LOTS mousea
aValues are expressed as the mean ± standard error of the mean (SEM).
Sulfatides
cn, the number of independent samples per group.
bDetermined through densitometric scanning of HPTLC plates as shown in Figures 27 and 28
dSignificantly different from the untreated HexA +/- group at P < 0.01 by One Way ANOVA.
eSignificantly different from the untreated HexA -/- group at P < 0.01 by One Way ANOVA.
CerebrosidesGA2
ND, not detectable.
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CHAPTER SIX 
Correction of lipid abnormalities in adult Sandhoff Mouse brain and 
spinal cord following CNS injection of AAV2/rh8 Hexα and β 
 
INTRODUCTION 
 Having established the utility of dual vector administration in the 
Tay-Sachs mouse model (Chapter 5), we sought to apply a similar 
approach to the Sandhoff mouse model.  While substantial correction 
has been observed using delivery of Hexb alone in a Sandhoff mouse 
model (Cachon-Gonzalez et al. 2006), it has been demonstrated 
repeatedly that dual vector administration produces more total Hex 
and specifically Hex A activity (Bourgoin et al. 2003, Arfi et al. 2005, 
Arfi et al. 2006).  To obtain optimal therapeutic effectiveness, we co-
administered AAV2/rh8 vectors encoding Hexα and Hexβ into the 
thalamus and deep cerebellar nuclei of one month old Sandhoff mice.  
AAV vector dramatically increased β-hexosaminidase enzymatic 
activity in brain, cerebellum, and spinal cord of Hexb-/- mice.  Lipid 
biochemistry showed evidence of substantial correction of GM2 storage 
and myelin-enriched lipid content.  Moreover, AAV therapy more than 
doubled the expected lifespan of Hexb-/- mice.  This study was an 
important step in our continued optimization of AAV therapies in 
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Sandhoff mice, and provides needed context for future studies with 
novel vector formations and dosages. 
 
MATERIALS AND METHODS 
Mice 
Mice were housed at the University of Cambridge Department of 
Medicine in the lab of our collaborator Dr. Begona Cachon-Gonzalez.  
Hexb-/- mice were generated, identified, and housed according to their 
previously described methods (Cachon-Gonzalez et al. 2006).   
 
AAV vector design 
The AAV vector used in this study was constructed as previously 
described by our collaborators in the lab of Dr. Cachon-Gonzalez 
(Cachon-Gonzalez et al. 2006). The AAV2 genome contains the murine 
Hexα or Hexβ cDNA under the control of Chicken β-actin (CBA) 
promoter and the woodchuck hepatitis post-transcriptional regulatory 
element (WPRE), packaged in the AAV rh8 capsid.    
 
Animal Procedures 
Stereotaxic coordinates (in mm) for the thalamus were A -2.0, L ± 
1.5, V -2.5 for the two injection sites.  Stereotaxic coordinates for the 
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cerebellum were A -6.0, L ± 1.5, V -3.0 for the two injection sites.  
Hyperosmotic concentrations of mannitol were added to the injections, 
as it has been shown to enhance vector delivery in murine brain 
(Bourgoin et al. 2003).  1 month old Hexb-/- mice received bilateral 
thalamic/cerebellar injections with 4.4 µl AAV2/rh8 α (2.42 x 1011 g.c.) 
+ 4.4 µl AAV2/rh8 β (3.95 x 1011 g.c.) + 3.2 µl 20% mannitol.  Mice 
were sacrificed seven months after injection, corresponding to 8 
months of age. 
 
Tissue Preparation 
Tissue was prepared as previously described and shipped to Boston 
College on dry ice for analysis (Cachon-Gonzalez et al. 2006). 
 
Enzyme Assays  
As previously described in chapters 3, 4, and 5. 
 
Total lipid isolation 
As previously described in chapters 3, 4, and 5. 
 
Sialic acid quantification   
As previously described in chapters 3, 4, and 5. 
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High-performance Thin Layer Chromatography 
As previously described in chapters 3, 4, and 5. 
 
Ganglioside and lipid quantification 
As previously described in chapters 3, 4, and 5. 
 
Statistics 
Untreated Hexb-/- and AAV-Hexα+β treated Hexb-/- mice were 
compared by student’s t-test for sialic acid content ganglioside and 
ganglioside distribution.  The data for 3 month old and 8 month old 
Hexb+/- mice is presented separately in these cases due to their 
differences in ganglioside content.  All experimental groups were 
compared using the One Way Analysis of Variance (ANOVA) for 
cerebroside and sulfatide content. 
 
RESULTS 
AAV vector increases β-Hexosaminidase activity in Sandhoff mouse 
CNS 
 Similar to our observations in Chapters 4 and 5, we found that 
AAV Hexα+β dramatically increased β-Hexosaminidase specific activity 
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in SD mouse brain, while conferring a more modest increase in spinal 
cord.  Cortical Hex activity was 6-fold to over 100-fold greater in AAV 
treated Hexb-/- mice than in untreated controls (Figure 27).  Hex 
activity was 1000-fold greater in cerebellum of AAV-treated Hexb-/- 
mice than in untreated controls (Figure 28).  Hex activity was about 
10-fold greater in spinal cord sections of AAV-treated Hexb-/- mice 
than in untreated controls (Figure 29) 
 
AAV vector partially corrects GM2 and GA2 storage in SD mouse CNS 
 The AAV-treated SD mice lived for 8 months before the 
termination of the study.  Therefore, direct comparisons of ganglioside 
distribution may reflect age-related differences along with differences 
from the administered gene therapy.  Total sialic acid content is 
substantially higher in cortex and cerebellum of untreated Hexb-/- 
mice compared to Hexb+/- controls, largely due to storage of GM2 
(Figures 30 and 31, Tables 12 and 13).  GM2 content is also greatly 
increased in spinal cord of Hexb-/- mice (Figure 32, Table 14).  Sialic 
acid content is significantly reduced in 8 month old AAV-treated Hexb-
/- mice cortex and cerebellum compared to untreated Hexb-/- mice 
(Tables 12 and 13).  GM2 content is significantly reduced, thought not 
completely eliminated, in cortex, cerebellum, and spinal cord of AAV-
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treated Hexb-/- compared to untreated Hexb-/- mice (Figures 30-32, 
Tables 12-14).  GA2 content was completely eliminated in cortex and 
lumbar spinal cord of AAV-treated Hexb-/- mice (Table 15).  GA2 
content was reduced by 79% and 64% in cerebellum and cervical 
spinal cord, respectively, in AAV-treated Hexb-/- mice (Table 15). 
 
AAV vector improves myelin-associated lipid content in SD mouse 
brain 
3 month old Hexb-/- mice have roughly half the cerebroside and 
sulfatide content of age matched and 8 month Hexb+/- mice (Figure 
33 and Figure 34).  AAV-Hexα+β significantly increased cerebroside 
and sulfatide content in Hexb-/- brain, and completely restored 
cerebellar sulfatides to normal levels (Figure 33 and Figure 34). 
 
DISCUSSION 
 At first glance, it would appear that pathology in Hexb-/- was not 
corrected to the same extent as Hexa-/- mice treated with Hexα+β 
(Chapter 5).  However, since we did not examine cerebellum and 
spinal cord in the previous study, direct comparisons can only be made 
in the cerebral cortex.  Hexb-/- mice store at least double the amount 
of GM2 at 3 months of age compared to their Hexa-/- counterparts 
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(Chapter 5, Table 12).  Given that the Hexb-/- increased their lifespan 
more than 100%, it is clear that the level of reduction of GM2 storage 
observed here is sufficient to delay symptom onset and correct myelin 
deficiencies in SD mouse models.  Going forward, we intend to try new 
bicistronic vectors that express both Hexα and Hexβ from the same 
promoter.  This will likely reduce the required viral load, as co-
infection will no longer be necessary for high-level production of Hex 
A. 
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Figure 27. Cortical coronal section (R1-R4) β-hexosaminidase activity 
in untreated Hexb+/- (HZ), untreated Hexb-/- (KO), and AAV-Hexα+β 
injected Hexb-/- (AAV) mice.  4-methyumbelliferyl-N-acetyl-B-D-
glucosaminide was used as the substrate.  Total Hex activity is 
expressed as nmol/hour/mg protein and the values are expressed as 
mean ± SEM.  The number of independent mice analyzed was 3-6 per 
group.  *, ** denotes a statistically significant difference from 
untreated Hexb-/- mice at P < 0.05 or 0.01, respectively, using a 
student’s t-test. 
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Figure 28. Cerebellar β-hexosaminidase activity in untreated Hexb+/- 
(HZ), untreated Hexb-/- (KO), and AAV-Hexα+β injected Hexb-/- 
(AAV) mice.  4-methyumbelliferyl-N-acetyl-B-D-glucosaminide was 
used as the substrate.  Total Hex activity is expressed as 
nmol/hour/mg protein and the values are expressed as mean ± SEM.  
The number of independent mice analyzed was 3-6 per group.  * 
denotes a statistically significant difference from untreated Hexb-/- 
mice at P < 0.05 using a student’s t-test. 
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Figure 29. Spinal cord (in descending order from cervical (2) to lumbar 
(8)) section β-hexosaminidase activity in untreated Hexb+/- (white 
bars), untreated Hexb-/- (black bars), and AAV-Hexα+β injected 
Hexb-/- (red bars) mice.  4-methyumbelliferyl-N-acetyl-B-D-
glucosaminide was used as the substrate.  Total Hex activity is 
expressed as nmol/hour/mg protein and the values are expressed as 
mean ± SEM.  The number of independent mice analyzed was 3-6 per 
group.    
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 Figure 30. Ganglioside distribution in cortex of untreated Hexb+/- 
(HZ), untreated Hexb-/- (KO), and AAV-Hexα+β injected Hexb-/- 
(AAV) mice.  The amount of ganglioside sialic acid spotted per lane 
was equivalent to 1.5 µg sialic acid.  The plate was developed in a 
single ascending run (90 min) with chloroform: methanol: water 
(55:45:10 v/v/v) containing 0.02% calcium chloride.  The bands were 
visualized by spraying with the resorcinol reagent and heating to 95°C. 
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Figure 31. Ganglioside distribution in cerebellum of untreated Hexb+/- 
(HZ), untreated Hexb-/- (KO), and AAV-Hexα+β injected Hexb-/- 
(AAV) mice.  The amount of ganglioside sialic acid spotted per lane 
was equivalent to 1.5 µg sialic acid.  The plate was developed in a 
single ascending run (90 min) with chloroform: methanol: water 
(55:45:10 v/v/v) containing 0.02% calcium chloride.  The bands were 
visualized by spraying with the resorcinol reagent and heating to 95°C. 
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Figure 32. Ganglioside distribution in upper (left plate) and lower (right 
plate) spinal cord of untreated Hexb+/- (HZ), untreated Hexb-/- (KO), 
and AAV-Hexα+β injected Hexb-/- (AAV) mice.  The amount of 
ganglioside sialic acid spotted per lane was equivalent to 1.5 µg sialic 
acid.  The plates were developed in a single ascending run (90 min) 
with chloroform: methanol: water (55:45:10 v/v/v) containing 0.02% 
calcium chloride.  The bands were visualized by spraying with the 
resorcinol reagent and heating to 95°C.  Spinal Cord sections 2 & 4 
(cervical) and sections 6 & 8 (lumbar) were pooled for the analysis. 
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Hexb +/- - 3 1 ND ND ND ND
Hexb +/- - 8 2 ND ND ND ND
Hexb -/- - 3 4 51.4 ± 4.7 46.4 ± 1.8 22.5 ± 3.3 45.4 ± 3.6
Hexb -/- AAVc 8 6 Trace 10.2 ± 3.3d 8.2 ± 1.9d ND
d Significantly different from untreated Hexb-/- mice at p < 0.05 by student's t-test.
ND, not detected
Strain Age (months)Treatment
c Mice received bilateral thalamic and cerebellar injections of 4.4 µl AAV2/rh8 Hex! (2.42 x 1011 g.c.) + 4.4 µl AAV2/rh8 Hex" (3.95 x 1011 
g.c.) + 3.2 µl 20% mannitol.
Spinal Cord (6/8)
Table 15. Effect of AAV vector on GA2 concentration in Sandhoff mouse CNS*
* Values are expressed as the mean ± SEM except when the number of independent samples is 2, where values are expressed as mean ± 
interquartile range.
a Asialo ganglioside were determined by densitometric scanning of HPTLC plates.
b n, the number of independent samples per group.
nb
Cerebrum Cerebellum Spinal Cord (2/4)
GA2a
(µg/mg dry weight)
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Figure 33. HPTLC of A) Neutral and B) Acidic lipids in AAV-treated 
Sandhoff mouse brain. The amount of neutral lipid spotted per lane 
was equivalent to 70 µg tissue dry weight.  The amount of acidic lipid 
spotted per lane was equivalent to 200 µg tissue dry weight.  The 
neutral and acidic plates were developed to heights of 4.5 and 6.0 cm, 
respectively, with chloroform: methanol: acetic acid: formic acid: 
water (35:15:6:2:1; v/v/v/v/v), then run to the top with hexane: 
diisopropyl ether: acetic acid (65:35:2; v/v/v). The bands were 
visualized by charring with 3% cupric acetate in 8% phosphoric acid 
solution.  CE – Cholesterol Esters; TG – Triglycerides; IS – Internal 
Standard (Oleyl Alcohol); Chol – Cholesterol; Cer – Ceramide; CB – 
Cerebrosides (doublet); PE – phosphatidylethanolamine; PC – 
Phosphatidylcholine; SM – Sphingomyelin.  FA – Fatty Acids; CL – 
Cardiolipin; PA – Phosphatidic Acid; Sulf – Sulfatides (doublet); PS- 
Phosphatidylserine; PI – Phosphatidylinositol. 
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Figure 34. Restoration of myelin-associated lipids following AAV vector 
gene therapy in SD mouse brain.  Neutral and Acidic lipids purified 
from right cortex and right cerebellum were spotted at 70ug and 
200ug, respectively, based on dry weight on HPTLC.  Values for 
cerebrosides and sulfatides were taken from densitometric scanning of 
HPTLC plates as shown in Figure 33.  Values are expressed as mean ± 
SEM.  N = 3, 4, and 6 mice per group for untreated Hexb+/- (HZ), 
untreated Hexb-/- (KO), and treated Hexb-/- (AAV) mice, respectively. 
*, ** denote a statistically significant difference (p<0.05 and p<0.01, 
respectively) from the untreated Hexb-/- (KO) mice using one-way 
ANOVA. 
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CHAPTER SEVEN 
Adeno-Associated Viral Gene Therapy Provides Global CNS Correction 
of Ganglioside Storage and Myelin Enriched Lipids in a Feline Model of 
Sandhoff Disease 
 
INTRODUCTION 
Feline Sandhoff Disease 
Sandhoff disease (SD) is a progressive and fatal neurodegenerative 
lysosomal storage disorder characterized by mutations in the β subunit 
(Hexb gene) of the heterodimeric enzyme β-hexosaminidase, leading 
to storage of ganglioside GM2 and asialo-GM2 (GA2).  Feline SD, 
conferred by a mutation in Hexb exon 14, closely models the clinical 
SD symptoms of GM2 ganglioside storage, demyelination, loss of 
motor coordination, and neuroinflammation. Adeno-associated viral 
(AAV) gene therapy has been shown to restore supranormal Hex 
enzymatic activity in murine and in vitro models of the GM2 
gangliosidoses.  In this study, we performed bilateral thalamic and 
deep cerebellar nuclei (DCN) injections of both AAV2/rh8-CBA-fHexa-
WPRE and AAV2/rh8-CBA-fHexb-WPRE into neonatal SD cats.  At 16 
weeks post-injection, we sacrificed a subset of the experimental 
animals to assess Hex enzymatic activity, ganglioside storage, and the 
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abundance of myelin-associated lipids in the CNS.   In all areas of the 
CNS assayed, we found that AAV vector significantly increased Hex 
activity (nmol/mg protein/hr) beyond untreated, age-matched normal 
and SD cats.  GM2 (µg sialic acid/100 mg dry weight) and GA2 
(µg/100 mg dry weight) content was reduced by >90% compared to 
untreated SD cats in cortex, cerebellum, thalamus, striatum, and 
lumbar spinal cord.   In cervical spinal cord, GM2 and GA2 content was 
reduced by >65%.  Myelin-associated cerebrosides and sulfatides were 
significantly increased in AAV-treated SD cat brain compared to 
untreated SD controls.  Cerebrospinal fluid (CSF) is an important 
diagnostic tool for biochemical assessments of therapeutic efficacy in 
living patients. AAV vector treatment significantly elevated Hex 
enzymatic activity and significantly reduced GM2 content in SD cat 
CSF.  These data confirm the utility of viral-mediated gene therapy for 
lysosomal storage disorders in larger animal models.  Hex activity and 
GM2 content in AAV-treated SD feline CSF mirror the patterns seen in 
CNS tissue, providing a reliable means of tracking therapeutic progress 
in potential clinical implementations. 
 
MATERIALS AND METHODS 
Cats 
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Cats were housed at the Auburn University College of Veterinary 
Medicine in the lab of Dr. Douglas Martin.  SD cats were identified and 
housed according to their previously described methods (Baek et al. 
2009).   
 
AAV vector design 
The AAV vector used in this study was constructed as previously 
described by our collaborators in the lab of Dr. Miguel Sena-Esteves 
(Broekman et al. 2006), (Broekman et al. 2007). The AAV2 genome 
contains the feline Hexα or Hexβ cDNA under the control of Chicken β-
actin (CBA) promoter and the woodchuck hepatitis post-transcriptional 
regulatory element (WPRE), packaged in the AAV8 capsid.    
 
Animal Procedures 
At 4-5 weeks of age, SD cats were anesthetized with ketamine (10 
mg/kg) and dexmedetomidine (0.04 mg/kg) administered through an 
intravenous catheter and maintained using isofluorane (0.5-1.5%) in 
oxygen delivered through an endotracheal tube.  Kittens were 
positioned using a Horsley-Clark stereotaxic apparatus (David Kopf 
Instruments).  The dorsal cranium was clipped and prepared 
aseptically. A single incision was made through the skin and 
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periosteum exposing the skull. Stereotaxic coordinates (in cm) for the 
thalamus relative to bregma were AP -0.7, ML ± 0.4, DV -1.6, and for 
the deep cerebellar nuclei (DCN) relative to lambda were AP 0.0, ML ± 
0.4, DV -1.25. The DV zero point was marked when the needle tip 
touched meninges.  
Vector was delivered using a Hamilton syringe (Harvard Apparatus, 
Holliston, MA) with a non-coring needle (22-25G).  The needle was 
advanced through the skull and into the target area manually at a rate 
of 1mm/second. For each thalamic injection site, a total of 70 µl was 
delivered in 10-20 µl aliquots at a rate of 2 µl/min. Between each 
aliquot, the injection needle was raised 0.15 cm, so that the final 
needle position was 1.15 cm ventral to meninges (~ 2.5mm ventral to 
the lateral ventricle). For each DCN, a total of 20 µl was injected at a 
single site at a rate of 2 µl/min.  AAV injections were performed by our 
collaborators at Auburn University. 
 
Tissue Preparation 
Cats were euthanized by pentobarbital overdose (100 mg/kg) and then 
transcardially perfused with cold, heparinized saline. Each brain was 
divided into coronal blocks of ~0.5cm from the frontal pole through 
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the cerebellum.  A punch biopsy was taken from each tissue and 
frozen for enzyme assays and lipid isolation. 
 
Histology 
Histological staining for Hex activity was performed by our 
collaborators as previously described (Broekman et al. 2007, Baek et 
al. 2010). 
 
β-Hexosaminidase Assay 
The Hex activity for each tissue section was determined as described 
in chapter 3. 
 
Isolation and Purification of Lipids 
Gangliosides, Neutral Lipids, and Asialo glycosphingolipids were 
separated as described in chapters 3 and 4. 
 
Analysis of Ganglioside and Cerebroside Content 
Lipids were analyzed by HPTLC as described in chapter 3.  
 
Analysis of Cerebrospinal Fluid 
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CSF enzymatic activity and gangliosides were separated as previously 
described in chapter 3, with the exception that no ion exchange 
column chromatography was performed before Folch partitioning.  
  
RESULTS 
AAV Vector increases Hex expression in SD cat brain 
Histological analysis reveals no detectable Hexb staining in SD 
cat brain (Figure 35A).  At 16 weeks, intense staining can be seen at 
the site of injection, with slightly less perfuse staining in sites distal 
from the cortical and cerebellar injections.  Quantitative analysis 
revealed a 2-50 fold increase in Hex specific enzymatic activity, with 
the majority attributable to Hex A enzyme activity (Figure 35B).  
Similar to the histological pattern, Hex activity was highest in sites 
proximal to the injection.  Interestingly, the expression of β-
galactosidase was slightly reduced in cats receiving AAV vector (Figure 
35C). 
 
AAV Vector corrected lipid abnormalities in SD cat brain 
The qualitative distribution of gangliosides for normal, SD, and 
AAV-Hexα+β injected SD cats is shown in Figures 36-39, and the 
distribution of brain neutral lipids is shown in Figure 40.  The 
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quantification of sialic acid, GM2, GA2, and cerebroside content is 
shown in Figure 41.  Total sialic acid content was dramatically higher 
in SD cat cortex, cerebellum, striatum, and thalamus, due to an 
accumulation of GM2 ganglioside (Figures 36-41).  Total sialic acid 
content was similar in brain of normal cats and SD cats that received 
AAV-Hexα+β (Figures 36-41).  GM2 and GA2 content were almost 
completely cleared (>90% reduction) in AAV-treated SD cat cortex, 
striatum, thalamus, and cerebellum section 22 (Figure 41).  GM2 
content was reduced by 75% in cerebellum section 20 (Figure 41). 
Myelin-enriched cerebrosides are almost completely absent in SD cat 
cortex (Figure 40 and Figure 41), as seen previously (Baek et al. 
2009). AAV vector generally conferred at least a 2-fold improvement in 
cerebroside content, with the exception again being cerebellum section 
20 (Figure 41). 
 
AAV vector improves spinal cord and CSF lipid storage 
Recombinant lysosomal enzyme delivered by AAV vectors has 
been previously shown to travel through CSF (Chapters 3 and 5) 
(Broekman et al. 2009).  Spinal cord in AAV-treated SD cats showed 
similar improvements in Hex enzymatic activity and reduction of GM2 
storage as the direct injection sites of the cerebral cortex and 
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cerebellum (Figure 42, Figure 43).  GM2 content was decreased by 
>65% and >95% in cervical and lumbar spinal cord, respectively.  
Finally, AAV vector significantly increased Hex activity in SD cat CSF 
(Figure 44).  Pooled CSF from several animals revealed a decrease in 
detectable GM2 content compared to untreated GM2 cats (Figure 45). 
 
Improved symptoms in AAV-treated SD cat at therapeutic endpoint 
SD cats were monitored for general onset of SD symptoms, which 
normally manifest at ~1.7 months after birth, with an inability to stand 
at the humane endpoint (~4.5 months).  SD cats that received AAV-
Hexα+β were still ambulatory at the experimental endpoint, with slight 
hindlimb weakness and intention tremors in 2 of the 3 animals.  The 
third animal appeared phenotypically normal.   
 
DISCUSSION 
The feline model for Sandhoff Disease is a closer approximation 
than the murine model to the challenge presented by the pathology of 
the human SD brain, due to increased tissue size, complexity, and 
ganglioside load (Bradbury et al, personal communication, Baek et al. 
2009).  Here we’ve shown the preliminary data for a comprehensive 
analysis of the SD cat cortex, cerebellum, and spinal cord after 
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administration of feline AAV vector.  Unlike the GM1 and GM2 
gangliosidosis mouse models discussed in chapters 4, 5, and 6, there 
appears to be considerable intra-tissue variability in the SD cat tissues 
examined.  The decrease in enzyme activity distal from the injection 
site has been shown histologically in mouse models (chapter 4, 
(Cachon-Gonzalez et al. 2006, Broekman et al. 2007), but perhaps 
due to lack of resolution or due to the size difference, these decreases 
had little effect when comparing multiple samples in the tissues of the 
same animal (Chapter 6). 
 The injection of recombinant feline Hex enzyme did not 
reproduce the pronounced inflammatory response and pathology of 
injecting the human enzyme (Bradbury et al, personal 
communication).  The reduction of GM2 ganglioside corresponded with 
a delayed onset (and reduced severity) of SD symptoms and 
seemingly normalized one of the animals in the study.  These data 
show that interspecies protein expression was likely the primary cause 
of the inflammatory response, instead of inherent pathogenic 
properties of the vector.  This hypothesis will be further put to the test 
in future experiments, as a new human Hexosaminidase vector will be 
introduced to nude mice in the lab of our collaborator Dr. Miguel Sena-
Esteves. 
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 The usefulness of CSF as a diagnostic tool for LSDs has been 
reported extensively (Bernheimer, Molzer & Deisenhammer 1977), 
(Fredman, Lekman 1997), (Yamato et al. 2004), (Gu, Tifft & Soldin 
2008).  Here we have shown that AAV vector confers a detectable and 
significant increase in Hex enzyme in the CSF, with a corresponding 
decrease in detectable GM2.  As CSF analysis is possible in larger 
animal models and clinically, we have now established it as a useful 
diagnostic tool for progression of CNS pathology in LSDs treated with 
AAV gene therapy.   
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Figure 35. AAV vector increases β-hexosaminidase enzymatic activity 
in 16-week SD cat brain.  A) Histological (GM2) staining of normal, 
GM2, and AAV-Hexα+β treated SD cat cerebrum and cerebellum. B) 
Hex A and total Hex specific activity (nmol/mg protein/hr) in AAV-
Hexα+β treated SD cat. C) β-gal specific activity (nmol/mg protein/hr) 
in AAV-Hexα+β treated SD cat.  Values are expressed as mean ± SEM, 
and are displayed as fold-increase over normal. 
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Figure 36. Ganglioside distribution in select cortex sections of 
untreated Normal (NM), untreated Sandhoff (SD), and AAV-Hexα+β 
injected Sandhoff (AAV) cats at 16 weeks.  The amount of ganglioside 
sialic acid spotted per lane was equivalent to 1.5 µg sialic acid.  The 
plates were developed in a single ascending run (90 min) with 
chloroform: methanol: water (55:45:10 v/v/v) containing 0.02% 
calcium chloride.  The bands were visualized by spraying with the 
resorcinol reagent and heating to 95°C.   
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Figure 37. Ganglioside distribution in cerebellum of untreated Normal 
(NM), untreated Sandhoff (SD), and AAV-Hexα+β injected Sandhoff 
(AAV) cats at 16 weeks.  The amount of ganglioside sialic acid spotted 
per lane was equivalent to 1.5 µg sialic acid.  The plates were 
developed in a single ascending run (90 min) with chloroform: 
methanol: water (55:45:10 v/v/v) containing 0.02% calcium chloride.  
The bands were visualized by spraying with the resorcinol reagent and 
heating to 95°C.    
  175 
  
  176 
Figure 38. Ganglioside distribution in striatum of untreated Normal 
(NM), untreated Sandhoff (SD), and AAV-Hexα+β injected Sandhoff 
(AAV) cats at 16 weeks.  The amount of ganglioside sialic acid spotted 
per lane was equivalent to 1.5 µg sialic acid.  The plates were 
developed in a single ascending run (90 min) with chloroform: 
methanol: water (55:45:10 v/v/v) containing 0.02% calcium chloride.  
The bands were visualized by spraying with the resorcinol reagent and 
heating to 95°C.   
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Figure 39. Ganglioside distribution in thalamus of untreated Normal 
(NM), untreated Sandhoff (SD), and AAV-Hexα+β injected Sandhoff 
(AAV) cats at 16 weeks.  The amount of ganglioside sialic acid spotted 
per lane was equivalent to 1.5 µg sialic acid.  The plates were 
developed in a single ascending run (90 min) with chloroform: 
methanol: water (55:45:10 v/v/v) containing 0.02% calcium chloride.  
The bands were visualized by spraying with the resorcinol reagent and 
heating to 95°C.    
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Figure 40. HPTLC of cortex and cerebellar neutral lipids in untreated 
Normal (NM), untreated Sandhoff (SD), and AAV-Hexα+β injected 
Sandhoff (AAV) cats at 16 weeks.  The amount of neutral lipid spotted 
per lane was equivalent to 70 µg tissue dry weight.  The plate was 
developed to a height of 4.5 cm with chloroform: methanol: acetic 
acid: formic acid: water (35:15:6:2:1; v/v/v/v/v), then run to the top 
with hexane: diisopropyl ether: acetic acid (65:35:2; v/v/v). The 
bands were visualized by charring with 3% cupric acetate in 8% 
phosphoric acid solution.  CE – Cholesterol Esters; TG – Triglycerides; 
IS – Internal Standard (Oleyl Alcohol); Chol – Cholesterol; Cer – 
Ceramide; CB – Cerebrosides (doublet); PE – 
phosphatidylethanolamine; PC – Phosphatidylcholine; SM – 
Sphingomyelin. 
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Figure 41. Influence of AAV vector on AAV-treated Sandhoff cat brain 
lipid content at 16 weeks.  A) Diagram of brain coronal blocks and 
quadrants.  Sections 3-18 represent cerebral cortex, while sections 19-
24 represent cerebellum. B) Total sialic acid content (µg/100 mg dry 
weight) in cortex, cerebellum, striatum, and thalamus of normal (n = 
1, green circles), SD (n = 2, red stars), and AAV-Hexα+β treated SD 
(n = 3, grey bars) cats.  C) GM2 content (µg sialic acid/100 mg dw). 
D) Cerebroside content (µg/mg dw).  Values are expressed as the 
mean for SD and AAV-treated SD samples. Error bars represent the 
SEM for AAV-treated SD samples.  Ctx, Cortex; Cb, cerebellum; Str, 
striatum; Tha, thalamus. 
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Figure 42. Ganglioside distribution in spinal cord of untreated Normal 
(NM), untreated Sandhoff (SD), and AAV-Hexα+β injected Sandhoff 
(AAV) cats at 16 weeks.  The amount of ganglioside sialic acid spotted 
per lane was equivalent to 1.5 µg sialic acid.  The plates were 
developed in a single ascending run (90 min) with chloroform: 
methanol: water (55:45:10 v/v/v) containing 0.02% calcium chloride.  
The bands were visualized by spraying with the resorcinol reagent and 
heating to 95°C.   
  
  185 
  
  186 
 
Figure 43. Influence of AAV vector on AAV-treated Sandhoff cat spinal 
cord (cervical and lumbar) lipid content at 16 weeks.  A) Hex 
enzymatic activity (nmol/mg protein/hr) in normal (n = 1, green 
circles), SD (n = 2, red stars), and AAV-Hexα+β treated SD (n = 3, 
grey bars) cats.  B) Total sialic acid content (µg/100 mg dry weight).  
C) GM2 content (µg sialic acid/100 mg dw). D) GA2 content (µg/100 
mg dw).  Values are expressed as the mean for SD and AAV-treated 
SD samples. Error bars represent the SEM for AAV-treated SD 
samples.  SC, spinal cord. 
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Figure 44. AAV vector increases Hex enzymatic activity in Sandhoff cat 
cerebrospinal fluid.  4-methyumbelliferyl-N-acetyl-B-D-glucosaminide 
was used as the substrate.  Total Hex activity is expressed as 
nmol/hour/mg protein and the values are expressed as mean ± SEM, 
or mean ± IQR for normal cats.  The number of independent cats 
analyzed was 2-3 per group.  Hex activity was significantly greater in 
CSF of GM2 cats injected with AAV-Hexα+β compared to untreated 
GM2 cats (p < 0.05). 
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Figure 45. AAV vector reduces GM2 content in Sandhoff cat 
cerebrospinal fluid.  GM2 sialic acid content was determined by 
densitometric scanning of HPTLC plates (data not shown).  CSF from 3 
untreated GM2 cats and 3 AAV-Hexα+β treated GM2 cats were pooled 
for the analysis.  GM2 content is expressed as ng sialic acid/ml CSF. 
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CHAPTER EIGHT 
 
CONCLUSIONS 
 My research has centered on optimizing therapies for the GM1 
and GM2 gangliosidoses.  To that end, we have performed biochemical 
analyses in several murine and feline models for lysosomal storage 
diseases.  We found that neural stem cell therapy has limited 
effectiveness in reducing ganglioside storage in juvenile mouse brain.  
Further, we found that substrate reduction therapy is more effective 
than neural stem cells in these young mice.  Lastly, we found that 
Adeno-associated viral vectors, when delivered directly to the brain, 
can effectively correct enzyme deficiency, ganglioside storage, and 
myelin lipid deficiencies in adult mice and cats.  In all AAV gene 
therapy models tested, the correction of lipid biochemistry 
corresponded to an increase in lifespan or a delay in symptom onset.   
In lipid storage diseases, the method of pathology is complicated 
by the potential for secondary storage material to cause pathology.  
Recent findings in mucopolysaccharidosis type IIIA mice (MPS3a) have 
shown that even when the primary storage material (heparan sulfate-
derived oligosaccharides) is corrected by stem cell or gene therapy, 
gangliosides GM2 and GM3 remain as secondary storage in separate 
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membrane compartments (Dawson et al. 2012, Lau et al. 2010).  In 
contrast, previous results in the GM1 gangliosidosis mouse have shown 
a near or complete correction of secondary cholesterol storage (as 
indicated by filipin fluorescence) when primary ganglioside storage is 
corrected by gene therapy (Broekman et al. 2007).  Methyl-β-
cyclodextrin, a reagent that corrects cholesterol storage in NPC1 
fibroblasts and mouse models, has no effect on filipin signal in GM1 
gangliosidosis fibroblasts or mouse tissue (Davidson et al. 2009, Abi-
Mosleh et al. 2009, Liu et al. 2010).  Our results have shown that the 
increase in intracellular GM1 ganglioside in β-gal -/- mouse brain does 
not necessarily coincide with a similar increase in cholesterol 
concentration.  Further, we have shown that filipin non-specifically 
binds to ganglioside GM1.  These results indicate that cholesterol 
storage may be overstated in GM1 gangliosidosis, and that any such 
storage may be insignificant for disease progression. 
Our lab, in collaboration with Miguel Sena-Esteves, has 
previously shown that AAV gene therapy was effective in reducing 
ganglioside storage when injected in neonatal and young adult mice 
(Broekman et al. 2007, Baek et al. 2010).  Here we show that a single 
injection of AAV-βgal into the cerebral ventricles of adult GM1 mice 
completely corrected CNS lipid pathology up to 8 months after 
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treatment.  This corresponded to an unprecedented increase in 
lifespan and motor coordination observed by our collaborators. 
In Sandhoff disease mice, the short turnaround (~4-6 weeks) 
from symptom onset to morbidity mirrors the severe pathology seen in 
early onset Tay-Sachs and Sandhoff Disease in humans.  Interventive 
therapies that are both tolerable and effective at early ages are 
desirable to treat these disorders.  NB-DNJ (miglustat) and Genz-
112638 (eliglustat tartrate) are already being used in clinical trials for 
non-neuronal Gaucher’s disease (Cox et al. 2003, Cox 2010, Shayman 
2010).  Our results show that NB-DGJ is equally as effective as NB-
DNJ at correcting ganglioside storage in juvenile SD mice.  We have 
recently had the opportunity to examine the effects of a novel 
eliglustat tartrate analog on ganglioside storage in SD mice (Larsen et 
al. 2012).  Similar to the findings of Larsen et al., we found that this 
new compound was capable of reducing GM2 storage in SD mouse 
brain at a fraction of the dosage of NB-DNJ or NB-DGJ (unpublished 
data).  We hope pursue more in depth studies on long term survival, 
dosage, and safety with this exciting new compound.   
While murine neural stem cells have already been established as 
effective therapies in adult Sandhoff mice, they appear to have no 
effect on neonatal GM2 storage, even in the presence of NB-DGJ (Lee 
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et al. 2007, Jeyakumar et al. 2009).  Our collaborators Jean Pyo-Lee 
and Evan Snyder have shown that intracranially transplanted mNSCs 
thrive at postnatal day 15, while we showed that this transplantation 
significantly increased β-hexosaminidase enzymatic activity.  Our 
results, showing partial correction of GA2, indicate that Hex A 
expression from mNSCs may be insufficient at p-15.  Stem cells that 
have been modified to overexpress Hex A enzyme may be more 
effective in cross-corrective therapy. 
 Previous studies using gene therapy have displayed conflicting 
results on whether providing a single subunit of the β-hexosaminidase 
heterodimer was sufficient to correct GM2 storage in either in vitro or 
in vivo models of the GM2 gangliosidoses (Cachon-Gonzalez et al. 
2006, Guidotti et al. 1998, Guidotti et al. 1999, Martino et al. 2002, 
Martino et al. 2005).  In collaboration with Begona Cachon-Gonzalez, 
and using a mouse model for late onset Tay-Sachs disease, we have 
shown that viral vectors expressing both α and β subunits are 
necessary for maximizing the production of β-hexosaminidase A (Hex 
A) in the brain.  Expression of both subunits dramatically increased 
enzymatic activity in CNS of Tay-Sachs and Sandhoff mice and 
significantly corrected ganglioside and myelin-associated lipid 
abnormalities. 
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 Lastly, we had the opportunity to collaborate with Douglas 
Martin as part of our efforts to test the effectiveness of gene therapy 
in larger animal models.  In cats injected intracranially with both 
subunits of β-hexosaminidase A, we observed a remarkable increase in 
enzymatic activity in the CNS.  This corresponded to a correction of 
GM2 ganglioside storage, and an elevation of cerebroside and sulfatide 
content.  Importantly, cerebrospinal fluid from treated cats exhibited 
reduced GM2 content, indicating that in can be used as a diagnostic 
tool in lieu of sacrificing animals for direct tissue assessment.  Cats 
treated with the vector generally experienced delayed symptom onset.  
It still remains to be determined what the long term survival prospects 
are for larger animal models treated with AAV therapy. 
 At this stage, we are still unsure about what effect, if any, AAV 
gene therapy has on the neuroinflammation associated with lipid 
storage diseases (Jeyakumar et al. 2003).  If the viral vector gene 
therapy is effective, we would expect to see a reduction in microglial 
activation and inflammatory cytokine production, as observed after 
treatment with non-steroidal anti-inflammatory drugs, caloric 
restriction, or the calorie restricted ketogenic diet (Jeyakumar et al. 
2004, Denny et al. 2006, Mulrooney et al. 2011).  NSAID and diet 
therapies could potentially be used in conjunction with gene therapy 
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(as they have been used in conjunction with SRT therapies), to 
improve survival further (Jeyakumar et al. 2004, Denny et al. 2010). 
 In summary, during my research into therapies for the GM1 and 
GM2 gangliosidoses, I’ve found that substrate reduction is effective for 
reducing ganglioside storage in murine brain, even when administered 
at younger ages.  Our results show that AAV mediated gene therapy is 
the most promising therapy thus far for delivering therapeutic levels of 
enzyme, and this concept has thus far proven effective in larger animal 
models.  Optimization of these therapies, and perhaps exploration of 
potential synergy between the two, appears to be the best approach 
as we push towards inevitably bringing these therapies to patients. 
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